[go: up one dir, main page]

CA2111035A1 - Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them - Google Patents

Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

Info

Publication number
CA2111035A1
CA2111035A1 CA002111035A CA2111035A CA2111035A1 CA 2111035 A1 CA2111035 A1 CA 2111035A1 CA 002111035 A CA002111035 A CA 002111035A CA 2111035 A CA2111035 A CA 2111035A CA 2111035 A1 CA2111035 A1 CA 2111035A1
Authority
CA
Canada
Prior art keywords
group
denotes
phenyl
alkyl
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002111035A
Other languages
French (fr)
Inventor
Frank Himmelsbach
Gunter Linz
Volkhard Austel
Helmut Pieper
Thomas Muller
Johannes Weisenberger
Brian Guth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2111035A1 publication Critical patent/CA2111035A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Abstract Carboxylic acid derivatives The invention relates to carboxylic acid derivatives of formula I

A - B - C - D - E - COORa (I) wherein A to E and Ra are defined as in claim 1, the tautomers thereof, the stereoisomers thereof including the mixtures thereof and the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly inhibitory effects on aggregation.

Description

- 1 2111~
60603.570 CarboxYlic acid derivatives This invention relates to novel carboxylic acid derivatives, their preparation, pharmaceutical compositions containing them and their use.

In EP-A-478328 and EP-A-478363 various phenylalanyl derivatives are described as fibrinogen antagonists. :

It has now been found that certain novel carboxylic acid derivatives have valuable pharmacological properties, particularly aggregation-inhibiting effects. These new compounds differ structurally from the compounds described in EP-A~478328 and EP-A-478363, in particular in the group B in formula I below.

Thus viewed from one aspect the present invention provides compounds of formula I

A - B - C - D - E - COORa (I) (wherein Ra denotes a hydrogen atom or a C15-alkyl, a C35-alkenyl, phenyl(C13-alkyl~, C57-cycloalkyl or a R1-C0-0-(R2CH)- -group;

Rl denotes a C~s-alkyl, C57-cycloalkyl, phenyl (C
alkyl), C15-alkoxy, C57-cycloalkoxy or phenyl group; ~

R2 denotes a hydrogen atom or a C14-alkyl, C57-cycloalkyl ~ :
or phenyl group; - , A denotes a C15-aminoalkyl group linked to group B via a carbon atom of A, or A denotes a 5-, 6- or 7-membered ::~
azacycloalkyl group linked to group B via a carbon a om of the azacycloalkyl group, or A denotes a quinuclidinyl or pyridyl group wherein, the nitrogen in the above-mentioned aminoalkyl or azacycloalkyl groups is optionally substituted by a group Rb, wherein the carbon atoms of the azacycloalkyl group are optionally substituted by 1 to 3 C13-alkyl groups or by an aminocarbonyl, cyano, R30- or R30-C0- group, wherein in a 6- or 7-membered azacycloalkyl group A a >CH- unit in the 4-position relative to the ring nitrogen is optionally replaced by a nitrogen atom, wherein in a 5-, 6- or 7-membered azacycloalkyl group A
a -CHz-CH< unit is optionally replaced by a -CH=C< unit and wherein in a piperazinyl or homopiperazinyl group A
a ring carbon adjacent to the nitrogen atom in the 4-position is optionally oxo-substituted; ,~

Rb denotes a C13-alkyl, phenyl(C13-alkyl), C24-alkanoyl, ~- .
trifluoroacetyl, (C1s-alkoxy)carbonyl, phenyl(C13- -alkoxy)carbonyl, (C3s-alkenyl)oxycarbonyl, or R1-C0-0-(R2CH)-0-C0- group;

R3 denotes a hydrogen atom or a Cl3-alkyl or phenyl(C13-alkyl) group; -~
::
B denotes a phenylene group optionally mono- or `~
disubstituted by fluorine, chlorine or bromine atoms, by trifluoromethyl groups, or by C13-alkyl, C13-alkoxy, C13- ~:
alkylsulphenyl, C13-alkylsulphinyl or C13-alkylsulphonyl ~ :
groups, wherein the substituents m~y be identical or different and wherein, additionally, 1 or 2 : ~
unsubstituted methine groups may each be replaced by an -N-atom, or B denotes a piperidinylene group, -C denotes a carbonyl, -CH2CH2-, -CH=CH-, -CH2-, -CH20-, : :
H2 ~ CONR4-, -CONR4-CH2-, -NR4CO-, -NR CO-NR -CH2NR4 , NR4CH2-, -S02NR4-, -SO2NR4-CH2- or -NR4SO2- group;

2111~3~
R4 denotes a hydrogen atom or a C13-alkyl or phenyl(C13-alkyl) group, or if C denotes a -CONR4- group bound to group B via the carbonyl group, R4 may also denote a methylene or 1,2-ethylene group bound to the carbon atom of group B in the ortho-position relative to the point of linkage of the -CONR4- group;

D denotes a phenylene group optionally mono- or disubstituted by fluorine, chlorine or bromine atoms, by trifluoromethyl groups, by C13-alkyl, C13-alkoxy, Cl3-alkylsulphenyl, C13-alkylsulphinyl or C13-alkylsulphonyl groups, wherein the substituents may be identical or different, and wherein additionally 1 or 2 unsubstituted methine groups may each be replaced by an N-atom, or D
denotes a C57-cycloalkylene group wherein one or two >CH- units may be replaced by an N-atom and additionally in an aza- or diazacyclohexylene ring thus formed, a ring carbon adjacent to a ring nitrogen is optionally ~ -oxo-substituted;

E denotes a bond, a Cl3-alkyleneoxy group bound to group D through the oxygen atom, a straight-chain C15-alkylene group optionally substituted by 1 or 2 C18-alkyl groups, or by a hydroxy, C18-alkoxy, RsNH-, R5N(C18alkyl) or R5N(phenylC13-alkyl) group, or E denotes a C25-alkenylene group optionally substituted by one or two Cl8-alkyl groups;

R5 denotes a hydrogen atom or a C18-alkyl, (Cl 4~
alkoxy)carbonyl, or phenyl(C13-alkoxy)carbonyl group~or a carbonyl or sulphonyl group substituted by a Cl8-alkyl ~ --group or by a C37-cycloalkyl, phenylCl3-alkyl or phenyl group, wherein each phenyl moiety in R5 is optionally mono- or disubstituted by fluorine, chlorine or bromine atoms, by trifluoromethyl groups, or by C13-alkyl, Cl3-alkoxy, Cl3-alkylsulphenyl, Cl3-alkylsulphinyl or Cl3-alkylsulphonyl groups and the substituents may be - ~ - 21~1~3~
identical or different;

wherein (i) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an Rb-NH-CH2- group, wherein Rb is a benzyloxycarbonyl group, then RaOOC-E-D-C- does not denote a 3-carboxy-phenylaminocarbonyl group (see EP-A-0372486 and J. Med.
Chem. 35: 4393-4407 (1992)), and (ii) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an Rb-NH-CH2- group, wherein Rb denotes a hydrogen atom or an acetyl group, the RaOOC-E-D-C- does not denote a phenylcarbonyl group substituted in the 4-position by a carboxymethyl, methoxycarbonylmethyl, 2-carboxy-ethyl, 2-methoxycarbonyl-ethyl or 2-ethoxycarbonylethyl group ~
(see EP-A-0044541, JP-A-5813553, JP-A-5939866, ~-JP-A-S846051 and Chem. Pharm. Bull. 33: 5059-5061 (1985)), and (iii) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an N~2-CH2-CH2- group, then RaOOC-E-D-C- does not denote a 4-ethoxycarbonyl- -phenylcarbonyl group (see DE-A-3718638~, and -, (iv) if the A-B- moiety denotes a 4-aminomethyl-phenyl-, 3-aminomethyl-phenyl-, 4-aminomethyl-3-methoxy-phenyl-or 3-aminomethyl-4-methoxyphenyl group, then RaOOC-E-D-C-does not denote a 4-ethoxycarbonylmethoxy-2,3-dichlorophenylcarbonyl group (see J. Med. Chem. 27:
1579-1587 (1984) and Diuretics: Chem. Pharmacol., Clin.
Appl., Proc. Int. Conf. Diuretics, 1st, 21-29 ~1984)), and ~ " 2111~3~

(v) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an NH2-CH2- or (CH3)3C0-C0-NH-CH2- group, then RaOOC-E-D-C- does not denote a 4-carboxyphenylmethoxy group (see Int. J. Pept.
Protein Res. 18: 451-458 (1981)), and (vi) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an NH2-CH2- group, then RaOOC-E-D-C- does not denote a 4-carboxy-phenylaminosulphonyl group (see Chem. Pharm. Bull -~Tokyo) 7: 734-739 (1959) and J. Chem. Phys. 32: 691-697 -(1960)), and (vii) if the A-B- moiety denotes a 4-(2-pyridyl)-phenyl- -or 4-(3-pyridyl)-phenyl group, then RaOOC-E-D-C- does not denote a 4-carboxy-phenylcarbonylamino, 4- -~
benzyloxycarbonyl-phenylcarbonylamino- or 2-(4-carboxy-phenyl)-ethyl group (see J. Med. Chem. 11: 2a5 (1968) and US-A-2837522), and (viii) if the A-B- moiety denotes a 3-(4-pyridyl)-phenyl -- -group, then RaOOC-E-D-C- does not denote a 2- ~ -(carboxymethyl)-phenylcarbonylamino group (see Farmaco 44: 721-729 (1989))) ~ -and the isomers (eg. tautomers and stereoisomers), isomer mixtures and salts thereof.

In formula I, where group D denotes an aza- or diazacyclohexylene ring this may be linked to groups C
and E via ring carbons and/or ring nitrogens of D.

Preferred compounds according to the invention include those of formula I wherein:

Ra denotes a hydrogen atom or a C1s-alkyl, phenyl(Cl3-alkyl) or Cs7-cycloalkyl group;

-`` 2111~3~

A denotes a Czs-aminoalkyl group linked to group B via a .
carbon atom of A, or a piperidinyl group linked to group ~.
B via a carbon atom of the piperidinyl group, or A .-denotes a quinuclidinyl or pyridyl group, wherein the : -:
nitrogen of the above-mentioned aminoalkyl or ~:
piperidinyl groups is optionally substituted by a group Rb, wherein the carbon atoms of the piperidinyl group are optionally substituted by methyl, cyano, carboxy, methoxycarbonyl or aminocarbonyl groups, ¦ and wherein in a piperidinyl A group a >CH- unit in the 4-position may be replaced by a nitrogen atom or a ~ . --CH2-CH< unit may be replaced by a -CH=C< unit; -:~:

Rb denotes a C13-alkyl, benzyl, (C1s-alkoxy)carbonyl, ;~:
benzyloxycarbonyl or CH3-CO-O-(CHz)-O-CO- group; :-.
B denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a C12-alkyl, --C12-alkoxy, C12-alkylsulphenyl, C12-alkylsulphinyl or :
C12-alkylsulphonyl group, or B denotes a pyridinylene or piperidinylene group;

C denotes a -CO-, -CH2CH2-, -CH=CH-, -CH2-, -CH20-, -OCH2-, -CONR4-, -NR4CO-, -NR4CO-NR4-, -CH2NR4-, -NR4CH2-, -SO2NR4- or -NR4SO2- group;

R4 denotes a hydrogen atom or a C12-alkyl or phenyl(C12-alkyl) group or, if C denotes a -CONR4 group bound to group B via the carbonyl group, R4 may also denote a methylene or l,2-ethylene group bound to the carbon atom of group B in the ortho- position relative to the point of linkage of the -CONR4 group;

D denotes a phenylene group optionally substituted by a chlorine or bromine atom, or by a C12-alkyl or C12-alkoxy group, or D denotes a cyclohexylene group in which one :

7 21111~3~
or two >C~- units may be replaced by N-atoms, and additionally, in a piperidinylene or piperazinylene D
group a ring carbon adjacent to a ring nitrogen is optionally oxo-substituted;

E denotes a bond, a methyleneoxy group bound to group D
through the oxygen atom, a 1,2-ethenylene group or a ~ , straight-chain C1s-alkylene group which may be substituted by a C17-alkyl group or by an R5NH- group;
and R5 denotes a hydrogen atom or a C17-alkylcarbonyl, :
benzylcarbonyl, C15-alkylsulphonyl or benzylsulphonyl - ~-group; .

wherein (iii) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an NH2-CH2-CH2- group, then RaOOC-E-D-C does not denote a 4-ethoxycarbonyl-phenylcarbonyl group, and (vii) if the A-B- moiety denotes a 4-(2-pyridyl)-phenyl-or 4-(3-pyridyl)-phenyl group, then RaOOC-E-D-C- does not denote a 4-carboxy-phenylcarbonylamino, 4-benzyloxycarbonyl-phenylcarbonylamino- or 2-(4-carboxy-phenyl)-ethyl group, and (viii) if the A-B- moiety represents a 3-(4-pyridyl)-phenyl group, then RaOOC-E-D-C- does not denote a 2-~(carboxymethyl)-phenylcarbonylamino group;

and the tautomers, stereoisomers tincluding mixtures ::
thereof) and salts thereof. :;~

21~1~33~

In formula I, where yroup D denotes a piperidinylene or piperazinylene ring this may be linked to groups C and E
via ring carbons and/or ring nitrogens of ~.

Particularly preferred compounds according to the invention include those of formula I wherein:

Ra denotes a hydrogen atom or a C14-alkyl, 2-phenylethyl or cyclohexyl group;

A denotes a C3s-aminoalkyl group linked to group B via a carbon atom of A, or a piperidinyl group linked to group B via a carbon atom of the piperidinyl group or A
denotes a quinuclidinyl or 4-pyridyl group, wherein the nitrogen atom in the above-mentioned piperidinyl group is optionally substituted by a group Rb, wherein the carbon atoms of the piperidinyl group are optionally substituted by methyl, cyano, carboxy, methoxycarbonyl or aminocarbonyl groups, and wherein in a piperidinyl A group a >CH- unit in the 4-position may be replaced by a nitrogen atom or a -CH2-CH< unit may be replaced by a -CH=C< unit;

Rb denotes a C13-alkyl, benzyl, (C14-alkoxy)carbonyl or CH3-CO-O-(CH2~-O-CO- group;

B denotes an optionally methyl- or methoxy- substituted ~ :
phenylene group or a 2,5-pyridinylene or 1,4-piperidinylene group; ~

C denotes a -CO-, -CH2CH2-, -CH=CH-, -CH2-, -CH20-, ;;::
I -OCH2-, -CONR4-, -NR4CO-, -NR4CO-NR4- or -CH2NR4- group or I an -SO2NR4- group wherein the SO2 moiety is linked to group B;

: !~

2111~3~ .
g R4 denotes a hydrogen atom or a methyl or 2-phenylethyl group or, if C denotes a -CON~4- group bound to group B
via the carbonyl group, R4 may also denote a methylene or l,2-ethylene group bound to the carbon atom of group B
in the ortho-position relative to the linkage point of the -CONR4- group;

D denotes a phenylene group or a cyclohexylene group in which one or two >CH- units may be replaced by N- atoms;

E denotes a bond, a methyleneoxy group bound to group D
through the oxygen atom, or a straight-chain C15-alkylene group which may be substituted by an RsNH-group;

R5 denotes a hydrogen atom or a (C1s-alkyl)carbonyl, C14alkyl-sulphonyl, or benzylsulphonyl group;

and the tautomers, stereoisomers (including the mixtures thereof) and salts thereof.

In formula I, where group D denotes a piperidinylene or piperazinylene ring this may be linked to groups C and E
via ring carbons and/or ring nitrogens of D. -~:
Especially preferred compounds according to the :
invention include those of formula I wherein -Ra denotes a hydrogen atom or a C14-alkyl or cyclohexyl group;

A denotes a piperidinyl or 3,4-dehydro-piperidinyl group linked to group B via the 4-position, wherein the nitrogen atom is optionally substituted by a group Rb or A denotes a 4-piperazinyl group optionally substituted by a group Rb in the l-position, or A denotes a quinuclidinyl group:

2 ~ 3 ~

Rb denotes a (C14-alkoxy)carbonyl group;

B denotes a phenylene group;

C denotes a -CONR4 group;

R4 denotes a hydrogen atom or a methyl group or, if C
denotes a -CONR4 group bound to group B via the càrbonyl group, R4 may also represent a methylene or 1,2-ethylene group bound to the carbon atom of group B in the ortho-position relative to the point of linkage of the -CONR4 group;

D denotes a 1,4-phenylene or 1,4-cyclohexylene group;

E denotes a bond or a 1,2-ethylene group optionally substituted by an R5NH- group; and denotes a ~C1s-alkyl)carbonyl or a C14-alkylsulphonyl qroup;

and the tautomers, stereoisomers (including mixtures thereof) and salts thereof.

More especially preferred compounds according to the invention include: '~

4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl~-piperidine, .;-, 4-[4-[[4-[2-(n-butanesulphonylamino)-2- ::
(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]~
piperidine, ~-4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]- :
aminocarbonyl]-phenyl]-piperidine, ''1' ' , ~ 2111~35 4-[4-[[4-[2-(n-butanesulphonylamino)-2-carboxyethyl]-phPnyl]-aminocarbonyl]-phenyl]-piperidine, 4-[3-[~4-[2-(n-butanesulphonylamino)-2-carboxyethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine and 4-[3-[[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine, and the tautomers, stereoisomers (including mixtures thereof) and salts thereof.

Viewed from another aspect, the invention also provides a process for preparing the compounds of the invention, said process comprising at least one of the following steps:

a) (to prepare compounds of formula I wherein Ra denotes a hydrogen atom) .

hydrolysing, pyrrolysing or hydrogenolysing a compound of formula II

A - B - C - D - E - COORa' (II) ~

(wherein - :
A, B, C, D and E are as hereinbefore defined and R~l has -~ ::
the meanings given for Ra hereinbefore, with the exception of the hydrogen atom);

b) (to prepare compounds of formula I, wherein A is substituted by a group Rb) reacting a compound of formula III

2111~3~

Al - B - C - D - E - COORa (III) (wherein B, C, D, E and Ra are as hereinbefore defined and A1 denotes a C15-aminoalkyl group linked to group B via a carbon atom or a 5-, 6- or 7-membered azacycloalkyl group linked to group B via a carbon atom, wherein the carbon atoms of the azacycloalkyl group may be substituted by 1 to 3 C~3-alkyl groups or by an aminocarbonyl, cyano, R30~ or R30-CO- group, wherein R~
is as hereinbefore defined) with a compound of formula IV

Rb Z1 (IV) (wherein . ~
Rb is as hereinbefore defined and : -Z1 denotes a nucleophilic leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom, or, if Z
is bound to a carbonyl group, Z1 may also denote a hydroxy, alkanoyloxy or alkyioxycarbonyloxy group, or in the presence of a reducing agent when Z1 together with an adjacent hydrogen atom of the group Rb denotes an oxygen atom); -~

c) (to prepare compounds of formula I, wherein Ra has the ~:
meanings given hereinbefore, with the exception of the hydrogen atom) ~: -'''~::'~ ~, reacting a compound of formula V
: ~
A - B - C - D - E - COOH (V) ~:
' - -(wherein :~
A, B, C, D and E are a6 hereinbefore defined) with a , 2llln~s compound of formula VI

Z - R ' (VI) (wherein Ral has the meanings given for Ra hereinbefore, with the exception of the hydrogen atom, and Z2 denotes a nucleophilic leaving group such as a halogen atom, e.g. a chlorine or bromine atom, or a sulphonyloxy group substituted at the sulphonyl group, e.g. a methanesulphonyloxy, methoxysulphonyloxy or toluenesulphonyloxy group, or a hydroxy group);

d) (to prepare compounds of formula I, wherein C denotes a -CH2-NH- group) reducing a compound of formula VII

A - B - CH=N - D - E - COORa (VII) --(wherein A, B, D, E and Ra are as hereinbefore defined);

e) (to prepare compounds of formula I, wherein C denotes a -CO-NR4- group) reacting a compound of formula VIII

A2 ~ B - COOH (VIII) (wherein B is as hereinbefore defined and A2 denotes a group A substituted at the nitrogen atom by an alkyl, aralkyl, alkanoyl, trifluoroacetyl or alkoxycarbonyl group) with an amine of formula IX

- - 1" _ 21~1~3~
R - NH - D - E - COOR ' (IX) (wherein D, E and R4 are as hereinbefore defined and Ral has the meanings given for Ra hereinbefore, with the exception of the hydrogen atom);

f) (to prepare compounds of formula I, wherein C denotes an -NR4-CO- group) ::, -reacting a compound of formula X ~ ~:

A - B - NH-R4 (X) (wherein R4 and B are as hereinbefore defined and A2 denotes a group A substituted at the nitrogen atom by an alkyl, aralkyl, alkanoyl, trifluoroacetyl or alkoxycarbonyl group) with a carboxylic acid of formula HOOC - D - E - COORa' (XI) ;

(wherein D and E are as hereinbefore defined and -Ral has the meanings given for Ra hereinbefore with the exception of the hydrogen atom); ~ -g) (to prepare compounds of formula I, wherein A denotes a C15-aminoalkyl group linked to group B via a carbon atom) reducing a compound of formula XII ~ :

A3 - B - C - D - E - COORa (XII) twherein B, C, D, E and Ra are as hereinbefore defined and ~:

2111~3~
- ~.5 -A3 denotes a cyano yroup or cyanoC14alkyl group);

h) (to prepare a compound of formula I wherein R4 denotes an optionally phenyl-substituted C12-alkyl group) alkylating a compound of formula I (wherein R4 is a hydrogen atom);

i) performing the process of any one of steps (a) to (h) above on a reagent having a protecting group and subsequently removing the protecting group used;

j) converting a compound of formula I into a salt thereof; and k) resolving a compound of formula I into its isomers.

The hydrolysis of step (a) is appropriately carried out either in the presence of an acid such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, acetic acid/hydrochloric acid, trichloroacetic acid or trifluoroacetic acid, or in the presence of a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent such as water, methanol, water/methanol, ethanol, water/ethanol, water/isopropanol, water/tetrahydrofuran or water/dioxane, at temperatures between -10C and 120C, e.g. at temperatures between ambient temperature and the boiling temperature of the reaction mixture. Upon -treatment with an organic acid such as trichloroacetic -acid or trifluoroacetic acid, any alcoholic hydroxy groups present may simultaneously be converted into a corresponding acyloxy group, such as a trifluoroacetoxy group.

During acid hydrolysis, depending on the conditions used, other hydrolytically cleavable groups present in a compound of formula II, such as the acetyl, 213.1~3.

trifluoroacetyl, benzoyl, tert.butyloxycarbonyl or benzyloxycarbonyl group may be simultaneously cleaved.

If a compound of formula II contains, for example, a tert.butyloxycarbonyl group, the tert.butyl group may also be cleaved by treating with an acid such as trifluoroacetic acid, hydrochloric acid, formic acid, p- -- -toluenesulphonic acid, sulphuric acid, phosphoric acid -or polyphosphoric acid, optionally in an inert solvent ~
such as methylene chloride, chloroform, benzene, ~-toluene, tetrahydrofuran or dioxane, preferably at temperatures between -10C and 120C, e.g. at ~-temperatures between 0 and 60C, or thermally, optionally in an inert solvent such as methylene -,~
chloride, chloroform, benzene, toluene, tetrahydrofuran or dioxane and optionally in the presence of a catalytic ~
amount of an acid such as p-toluenesulphonic acid, ~ --sulphuric acid, phosphoric acid or polyphosphoric acid, preferably at the boiling temperature of the solvent -~
used, e.g. at temperatures between 40C and 100C.

If a compound of formula II contains, for example, a benzyloxycarbonyl group, the benzyl group may also be hydrogenolytically cleaved in the presence of a ~--hydrogenation catalyst such as palladium/charcoal, in a suitable solvent such as methanol, ethanol, ethanol/water, glacial acetic acid, ethyl acetate, dioxane or dimethylformamide, preferably at temperatures between 0 and 50C, e.g. at ambient temperature, under a -~
hydrogen pressure of 1 to 10 bar. During hydrogenolysis, other groups may also be reduced at the same time, e.g. a nitro group may be reduced to an amino group or a benzyloxy group to a hydroxy group, or a benzylamino group into an amino group. Furthermore, C=C
double bonds may simultaneously be hydrogenated into single bonds.

2111~33~

The reaction of step (b) is preferably carried out in a suitable solvent, optionally in the presence of a ba~e or optionally in the presence of an acid activating agent or in the presence of a reducing agent at temperatures between -30 and 150C.

If Z1 denotes a nucleophilic leaving group, the reaction of step (b) is conveniently carried out in a solvent or mixture of solvents such as water, tetrahydrofuran, tetrahydrofuran/water, dioxane, dioxane/water, methylene chloride, chloroform, ethyl acetate or dimethylformamide, conveniently in the presence of a base such as sodium carbonate, potassium carbonate or sodium hydroxide solution or in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine, N-methyl-morpholine or pyridine, which may simultaneously be used as solvent, optionally in the presence of a reaction accelerator such as potassium iodide at temperatures between -30 and 100C, but preferably at temperatures between -10 and 80C.

If Zl denotes a hydroxy group, the reaction of step (b) is conveniently carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionylchloride, trimethylchlorosilane, hydrochloric acid, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid, :
phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodi- : -, imide/N-hydroxysuccinimide, 2-(lH-benzotriazolyl)-1,1,3,3-tetramethyl-uronium salts, N,N'-carbonyldiimidazole, N,N'-thionyldiimidazole or ~ :~
triphenylphosphine/carbon tetrachloride, optionally in ~-- 18 - 21110~5 - :-, the presence of dimethylaminopyridine or l-hydroxy-benzotriazole, appropriately at temperatures between 0 and 150C, preferably at temperatures between 0 and -50C.

If Z1 together with an adjacent hydrogen atom of the group Rb denotes an oxygen atom, the reductive alkylation of step (b) is conveniently carried out in a suitable solvent such as methanol, ethanol, tetrahydrofuran, :
dioxane, acetonitrile or mixtures thereof with water, in the presence of a suitable reducing agent such as formic -:~ :-acid or a suitable complex metal hydride, but preferably in the presence of sodium cyanoborohydride, or with :- :
hydrogen in the presence of a hydrogenation catalyst ~
such as palladium/charcoal, at temperatures between o -:
and 50C, but preferably at ambient temperature. . ~:
- :~:' ' If Z2 denotes a halogen atom or a sulphonyloxy group :~
substituted at the sulphonyl group, the reaction of step ~
(c) is expediently carried out in a solvent such as ~:
tetrahydrofuran, dioxane, methylene chloride, chloroform, ethyl acetate, dimethylsulphoxide or dimethylformamide, appropriately in the presence of a ~- :
base such as sodium carbonate, potassium carbonate or ~:.
sodium hydroxide solution or in the presence of a ~
tertiary organic base such as triethylamine, N-ethyl- - :
diisopropylamine or N-methyl-morpholine, which may simultaneously serve as solvent, optionally in the presence of a reaction accelerator such as potassium iodide, at temperatures between -30 and 100C, but preferably at temperatures between -10 and 80C.

If Z2 denotes a hydroxy group, the reaction of step (c) is preferably carried out using the compound of formula VI as solvent, in the presence of thionylchloride or an acid such as hydrochloric acid or sulphuric acid, at temperatures between -10C and 100C, preferably at - 19 - 2111~
temperatures between 0C and 50C.

The reduction oE step (d) is preferably carried out in a suitable solvent such as methanol, methanol/water, methanolJammonia, methanol/water/ammonia, methanol/hydrochloric acid, methanol/ethereal hydrochloric acid, ethanol, ethyl acetate, ether, tetrahydrofuran, dioxane, dimethylformamide or glacial acetic acid, in the presence of catalytically activated hydrogen, e.g. hydrogen in the presence of Raney nickel, platinum or palladium/charcoal, or in the presence of a metal hydride such as sodium borohydride, sodium -cyanoborohydride or lithium borohydride, at temperatures between -20'C and 100C, preferably at temperatures between 0C and 60C.

The reaction of step (e) is conveniently carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, dimethylsulphoxide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, optionally in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionylchloride, trimethylchlorosilane, hydrochloric acid, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid, ~ : , phosphorus trichloride, phosphorus pentoxide, N,N'- -~
dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, 2-(lH- -~
benzotriazolyl)-1,1,3,3-tetramethyl-uronium salts, N,N'- .
carbonyldiimidazole, N,N'-thionyldiimidazole or triphenylphosphine/carbon tetrachloride, optionally in the presence of dimethylaminopyridine or l-hydroxy- ;. :
benzotriazole and/or a base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine, conveniently at temperatures between -10 and 150C, preferably at temperatures between 0 and 50C. ;~

~ ~, '~'';' '~ ", 2 1 ~

The reaction of step (f) is conveniently carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, dimethylsulphoxide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, optionally in the presence of a dehydrating agent, e.g. in the presence o~
isobutyl chloroformate, thionylchloride, trimethylchlorosilane, hydrochloric acid, sulphuric .
acid, methanesulphonic acid, p-toluenesulphonic acid, -phosphorus trichloride, phosphorus pentoxide, N,N'- ::
dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, 2-(lH-benzotriazolyl)-1,1,3,3-tetramethyl-uronium salts, N,N'-carbonyldiimidazole, N,N'-thionyldiimidazole or triphenylphosphine/carbon tetrachloride, optionally in -~
the presence of dimethylaminopyridine or l-hydroxy- ~.
benzotriazole and/or a base such as triethylamine, N- -ethyl-diisopropylamine or N-methyl-morpholine, conveniently at temperatures between -10 and 150C, preferably at temperatures between 0 and S0C.

The reduction of step (g) is preferably carried out in a - .
suitable solvent such as methanol, methanol/water, -.
methanol/water/ammonia, ethanol, ether, tetrahydrofuran, dioxane or dimethylformamide, optionally with the -addition of an acid such as hydrochloric acid, in the .
presence of catalytically activated hydrogen, e.g. ~- ~
hydrogen in the presence of Raney nickel, platinum or .: ~:
palladium/charcoal, or in the presence of a metal hydride such as sodium borohydride, lithium borohydride ~ :
or lithium aluminium hydride, at temperatures between 0 and 100C, preferably at temperatures between 20 and ~:
80C.

The alkylation of step (h) is conveniently carried out with a suitable halide such as methyliodide, ethylbromide, benzylchloride or phenylethylbromide, ~-'''"'`

~ ~ . . " . .. . . . . ..... . .. . ..

:" 2111~5 preferably in a solvent such as methylene chloride, tetrahydrofuran, dioxane, dimethylsulphoxide or dimethylformamide, optionally in the presence of a base such as sodium carbonate, potassium carbonate or sodium hydroxide solution or in the presence of a tertiary organic base such as N-ethyl-diisopropylamine or N-methyl-morpholine, which may simultaneously be used as solvent, at temperatures between -30 and 100C, but preferably at temperatures between -10 and 80C.

During the reactions described hereinbefore, reactive groups such as hydroxy, carboxy, amino, alkylamino or imino groups may be protected by means of conventional protecting groups which are removed by cleaving after the reaction.

For example, the protective group for a hydroxy group '-may be a trimethylsilyl, acetyl, benzoyl, tert.butyl, trityl, benzyl or tetrahydropyranyl group, the protecting group for a carboxyl group may be a trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or `~ -tetrahydropyranyl group, and the protecting group for an amino, alkylamino or imino group may be an acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert.- -butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and for the amino group a phthalyl group may also be considered.

The optional subsequent cleaving of a protecting group may, for example, be carried out hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide or by ether cleaving, e.g. in the presence of iodotrimethylsilane, at temperatures between - 22 _ 2 1 1 ~ ~ ,3 ~
0 and 100C, preferably at temperatures between 10 and 50C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl group may for example be cleaved hydrogenolytically, eg.
using hydrogen in the presence of a catalyst such as palladium/charcoal in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, -dimethylformamide/acetone or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid, at temperatures between 0 and 50C, but preferably at ambient temperature, under a hydrogen pressure of 1 to 7 bar, preferably 3 to 5 bar. During hydrogenolytic cleaving of benzyl groups, any CzC-double bonds present in a compound of formula II may simultaneously be hydrogenated. For example, an N-benzyl-dehydro-piperidyl group may be converted into a piperidyl group in this way. -A methoxybenzyl group may also be cleaved in the presence of an oxidising agent such as cerium(IV)-ammonium nitrate, in a solvent such as methylene chloride, acetonitrile or acetonitrile/water, at temperatures between 0 and 50C, but preferably at ambient temperature.

A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as - --trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxane, ether or dioxane/ether.

!
, 21~1133~

A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxane, at temperatures between 20 and 50C.

An allyloxycarbonyl group is cleaved by treating with a catalytic amount of tetrakis-(triphenylphosphine)-palladium(0), preferably in a solvent such as tetrahydrofuran and preferably in the presence of an excess of an allyl group acceptor such as morpholine or 1,3-dimedone, at temperatures between 0 and 100C, ~-preferably at ambient temperature and under inert gas, or by treating with a catalytic amount of tris- :
(triphenylphosphine)-rhodium(I)chloride, in a solvent ~ .
such as aqueous ethanol and optionally in the presence of a base such as 1,4-diazabicyclo[2.2.2]octane, at -~
temperatures between 20 and 70C.

Furthermore, the compounds of formula I obtained may be resolved into their enantiomers and/or diastereomers. ;~

Thus, for example, the cis/trans mixtures obtained may -:
be resolved by chromatography into the cis and trans ~ i~
isomers thereof and the compounds of formula I which ~:
occur in racemate form may be separated by conventional .
methods (see Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) .
into their optical antipodes, and compounds of formula I ~-having at least 2 stereogenic centres may be separated on the basis of their physical-chemical differences using known methods, e.g. by chromatography and/or fractional crystallisation, into the diastereomers thereof, which, if they occur in racemic form, may subsequently be separated into the enantiomers as mentioned above.

- 2~ _ 2 ~
The separation of enantiomers is preferably effected by column separation on chiral phases or by recrystallisation from an optically active solvent or by reaction with optically active substances (especially acids and the activated derivatives thereof or alcohols), which form salts or derivatives such as esters or amides with the racemic compound, and separation of the diasteromeric salt mixture or derivative thus obtained, e.g. on the basis of their different solubilities, whilst the free antipodes may be released from the pure diastereomeric salts by the action of suitable agents. Particularly useful, optically active acids include, for example, the D- and ~
L-forms of tartaric acid, and dibenzoyltartaric acid, -di-o-tolyl tartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid and ~ -quinic acid. Examples of optically active alcohols include for example (+)- or (-)-menthol and examples of optically active acyl groups in amides include, for example, (+)- or (-)-menthyloxycarbonyl.
: : -Moreover, the compounds of formula I obtained may beconverted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof with inorganic or organic acids. Examples of suitable acids include hydrochloric acid, hydrobromic -acid, sulphuric acid, phosphoric acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

In addition, the compounds of formula I thus obtained, if they contain a carboxyl group, may subsequently, if desired, be converted into the addition salts thereof with inorganic or organic bases, more particularly, for pharmaceutical use, into the physiologically acceptable addition salts thereof. Examples of suitable bases include sodium hydroxide, potassium hydroxide, ammonia, 2 ~

cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

The starting compounds used in the process of the invention are known or may be obtained by conventional techniques (see Examples I to XXIV).

As mentioned above, the compounds of the invention have -valuable properties. Thus, the compounds of formula I, wherein A represents an aminoalkyl, aza- or diazacycloalkyl group optionally substituted at the nitrogen, or represents a pyridyl or quinuclidinyl group or a group which may optionally be converted in vivo ~-into an aminoalkyl, aza- or diazacycloalkyl group, e.g. :
an amino, aza- or diazacycloalkyl group substituted at the nitrogen by an alkoxycarbonyl, alkenyloxycarbonyl, :-aralkoxycarbonyl, alkylcarbonyl, ~ :
trifluoromethylcarbonyl, alkanoyloxymethoxycarbonyl, cycloalkanoyloxymethoxy-carbonyl or aralkanoyloxymethoxycarbonyl group and -COORa denotes a .
carboxyl group or a group which may be converted in vivo into a carboxyl group, e.g. an alkoxy, alkenyloxy, phenylalkoxy, cycloalkyloxy, alkanoyloxyalkoxy, cycloalkanoyloxyalkoxy, phenylalkanoyloxyalkoxy, benzoyloxyalkoxy, alkoxycarbonyloxyalkoxy or cycloalkyloxycarbonyloxy-alkoxycarbonyl group, have valuable pharmacological properties, and in addition to having an inhibitory effect on inflammation and bone degradation, they have in particular antithrombotic, antiaggregatory and tumour- or metastasis-inhibiting effects.

Viewed from a further aspect the invention thus provides a pharmaceutical composition comprising a compound of formula I or a physiologically acceptable salt thereof together with at least one physiologically acceptable carrier or excipient.

.~

21~1~3~j Viewed from a still further aspect the invention also provides the use of a compound of formula I or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in combating .
inflammation, bone degradation, tumours, metastases, thrombosis and aggregation-related conditions.

Viewed from a yet still further aspect the invention provides a method of treatment of the human or non~
human, preferably mammalian body to combat inflammation, -bone degradation, tumours, metastases, thrombosis and -:
aggregation-related conditions, said method comprising administering to said body a compound of formula I or a physiologically acceptable salt thereof.

By way of example, the biological activity of the compounds according to the invention were investigated as follows: :

211103~

1. Competitive binding of 3H-BIBU 52/test substance to human thrombocytes:

A suspension of human thrombocytes in plasma is incubated with 3H-BIBU 52 ~3H-sIBU 52, which is disclosed in DE-A-4214245 is (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-[(carboxyl)methyl]-2- -pyrrolidinone[3-3H-4-biphenylyl] and is used in place of the conventional 12sI fibrinogen ligand] and various concentrations of the test substance. The free and bound ligand are separated by centrifuging and ~-quantified by scintillation counting. The inhibition of 3H-BIBU 52 binding by the test substance is determined from the measurements obtained.

In order to do this, donor blood is taken from an anticubital vein and anticoagulated with trisodium citrate (final concentration 13 mM). The blood is centrifuged for 10 minutes at 170 x g and the supernatant platelet-rich plasma (PRP) is removed. The remaining blood is vigorously centrifuged once more in order to obtain plasma. The PRP is diluted 1:10 with autologous plasma. 750 ~l are incubated with 50 ~l of physiological saline solution, 100 ~1 of test substance solution, 50 ~l of l4C-sucrose (3,700 Bq) and 50 ~l of ;~
3H-BIBU 52 (final concentration: 5 nM) at ambient temperature for 20 minutes. In order to measure the ~ -non-specific binding, 5 ~l of BIBU 52 (final concentration: 30 ~M) are used in place of the test -substance. The samples are centrifuged for 20 seconds at 10,000 x g and the supernatant is poured off. 100 ~l thereof are measured in order to determine the free ligand. The pellet is dissolved in 500 ~l of 0.2N NaOH, 450 ~l are mixed with 2 ml of scintillator and 25 ~1 of 5N HCl and measured. The residual plasma remaining in the pellet is determined from the 14C-content and the ~-bound ligand is determined from the 3H-measurement.

1, .,' ~`

2111~3~
~ 2~ -After the non-specific binding has been deducted, the pellet activity is plotted against the concentration of the test substance and the concentration for a 50%
inhibition of binding is determined.

2. Antithrombotic activity Method Thrombocyte aggregation is measured using the method of Born and Cross (J. Physiol. 170: 397 (1964)) in platelet-rich plasma taken from healthy volunteers. To inhibit coagulation, the blood is mixed with 3.14%
sodium citrate in a volume ratio of 1:10.

Collaqen-induced aqqreqation The pattern of the decrease in optical density of the platelet suspension is photometrically measured and recorded after the addition of the aggregation-triggering substance. The rate of aggregation is determined from the angle of inclination of the density curve. The point on the curve where there i5 maximum light transmittance is used to calculate the optical density.

The concentration of collagen used is as small as possible but sufficient to produce an irreversible :~
reaction curve. Standard commercial collagen produced by Hormonchemie of Munich is used. Before the addition of the collagen the plasma is incubated for 10 minutes with the substance at 37C.

From the concentration/activity curve the EC50 is determined, which indicates the concentration giving a 50% change in the optical density in terms of the inhibition of aggregation.

- 29 _ 2111~3~
The following table shows the results which were obtained:

Substance Competitive binding Inhibition of (Example No.) of 3H-BIBU 52/test platelet substance to humanaggregation thrombocytes EC50 [nM~
ICso [nM]

2.1>100 000 3 300 2.2 4 500 3 300 3.1 1 400 2 400 ~ -3.3 17 260 3.4 2 000 5 800 3.6 14 12~

The inhibition of thrombocyte aggregation after oral administration of the test substance is determined ex -~
vivo on Rhesus monkeys.

Directly before the oral administration of the test substance suspended in Natrosol, a blood sample is taken from the cubital vein of the animals to provide a ~ -~
reference value. At specified times after the administration of the substance, fresh blood samples are ~
taken and investigated as follows. -- -Whole blood, mixed with 3.14% sodium citrate in a ratio by volume of 1:10 is centrifuged at 200 x g for 15 minutes. The supernatant, platelet-rich plasma, is carefully removed. From the sediment which is rich in erythrocytes, the platelet-depleted plasma is obtained -~
as supernatant, by centrifuging at 4000 x g for lO ;~

::~

~!x _ 30 _ 2111~3~
minutes.

The thrombocyte aggregation triggered with collagen (Hormonchemie, Munich; 2 ~g/ml final concentration in platelet-rich plasma) in these ex vivo samples is measured photometrically using the method of Born and Cross ~J. Physiol. l70: 397 (1964)). The maximum light transmittance of the platelet-rich plasma, measured after collagen stimulation, is compared with the reference value in order to determine the inhibition of aggregation at the various times of blood sampling after the administration of the substance, relative to the reference value.

The compounds of Examples 2 and 5(2) inhibit the collagen-induced thrombocyte aggregation ex vivo for more than 2 hours after the oral administration of 1 mg/kg.

The compounds according to the invention are well tolerated because after intravenous administration of 30 mg/kg of the compounds of Examples 2 and 3 to three mice in each case, no animals died.
., ~ , In the light of their inhibitory effect on cell-cell or cell-matrix interactions, the compounds of formula I and the physiologically acceptable addition salts thereof are suitable for combating or preventing diseases in which smaller or greater cell aggregates occur or in which cell-matrix interactions play a part, e.g. in treating or preventing venous and arterial thrombosis, cerebrovascular diseases, lung embolism, cardiac infarction, arteriosclerosis, osteoporosis and the metastasis of tumours and the treatment of genetically caused or acquired disorders of cell interactions with one another or with solid structures. They are also suitable for parallel therapy in thrombolysis with - 31 _ 2111~3~
fibrinolytics or vascular interventions such as transluminal angioplasty or in the treatment of shock, psoriasis, diabetes and inflammation.

For treating or preventing the diseases mentioned above, the dosage is between 0.1 ~g and 30 mg/kg of body weight, preferably 1 ~g to 15 mg/kg of body weight, given in up to 4 doses per day. For this purpose the compounds of the invention, optionally in conjunction with other active substances such as thromboxane receptor antagonists and thromboxane synthesis inhibitors or combinations thereof, serotonin antagonists, ~-receptor antagonists, alkylnitrates such as glycerol trinitrate, phospho-diesterase inhibitors, prostacyclin and the analogues thereof, fibrinolytics such as tPA, prourokinase, urokinase, streptokinase, or anticoagulants such as heparin, dermatane sulphate, activated protein C, vitamin K antagonists, hirudine, inhibitors of thrombin or other activated clotting factors, may be incorporated together with one or more inert conventional carriers and/or diluents, e.g. corn ~-starch, lactose, sucrose, microcrystalline cellulose, ~-magnesium stearate, polyvinylpyrrolidone, citric acid, --tartaric acid, water, water/ethanol, water/glycerol, -~
water/sorbitol, water/polyethyleneglycol, propyleneglycol, stearylalcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, into conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories.
:.
The following Examples are provided to illustrate the invention in a non-limiting fashion. Percentages and ratios are by weight unless otherwise indicated except eluant ratios which are by volume~

- 32 - 21~1~3~
Preparation of the starting compounds:

Example I

4-(4-Carboxyphenyl)-piperidine-hydrochloride 157.4 g of oxalylchloride are added dropwise to a solution of 63.0 g of 1-acetyl-4-phenyl-piperidine in 1000 ml of methylene chloride, with thorough stirring, at -10 to -20C. Then 46.7 g of aluminium chloride are added. The mixture is stirred for 1 hour at -10C and a further 82.7 g of aluminium chloride are added. After another 2 hours the cooling bath is removed and the mixture is stirred for 24 hours at ambient temperature. -The reaction solution is carefully stirred into about 4 litres of ice/water and the aqueous phase is extracted twice with methylene chloride. The combined organic phases are washed with water, dried over sodium sulphate and the solvent is removed under reduced pressure. The residue remaining is dissolved in 2.5 litres of 2N -~ -sodium hydroxide solution with vigorous stirring. Ice -~
is added to the dark aqueous solution and it is acidified with conc. hydrochloric acid. The precipitate is suction filtered, washed with water and refluxed for 5 hours in 2 litres of 6N hydrochloric acid. The solvent is removed under reduced pressure. The solid remaining is triturated with a little water and suction filtered.
Yield: 40.5 g (54% of theory), Melting point: > 300C
Rf value: 0.07 (si.lica gel; methylene chloride/methanol/
conc. ammonia = 4:1:0.25) _ 33 _ 2111~3~
Example II

l-tert.Butyloxycarbonyl-4-(4-carboxyphenyl)-piperidine -47.5 g of 4-(4-carboxyphenyl)-piperidine-hydrochloride are carefully added to 16.4 g of sodium hydroxide in 300 ml of water. The suspension is diluted with 500 ml of dioxane and 250 ml of water. Then 54.6 g of di-tert.butyl pyrocarbonate are added in batches. The mixture is stirred for 16 hours at ambient temperature. :~
The precipitate is suction filtered and the filtrate is partially concentrated by evaporation under reduced pressure. The precipitate and the remaining aqueous ~ ~
filtrate are combined and diluted with 1 litre of water. - ~-The aqueous phase is adjusted to pH 2 using saturated -:~
potassium hydrogen sulphate solution and extracted twice with ethyl acetate. The combined ethyl acetate phases are washed with saturated saline solution, dried over sodium sulphate and the solvent is removed under reduced pressure. The crude crystalline product is triturated :~
with a little ethyl acetate, suction filtered and dried.
Yield: 54.0 g (90% of theory), Melting point: 172~174C
R~ value: 0.73 (silica gel; ethyl acetate/cyclohexane =

Example III

Methyl 3-(4-aminophenyl)-2-(n-butylsulphonylamino)-propionate 19 g of methyl 2-(n-butanesulphonylamino)-3-(4-nitro-phenyl)-propionate in 200 ml of ethyl acetate are treated with hydrogen at 5 bars pressure in the presence of 2 g of 10% palladium/charcoal for 1.5 hours at ambient temperature. The catalyst is filtered off, the ~-~
filtrate is evaporated down and the residue is used 211 ~03~
- 3~ -without further purification.
Yield: 17.8 g (100% of theory), Rf value: 0.43 (silica gel; cyclohexane/ethyl acetate =

The following compound is obtained analogously:

(1) Methyl 3-(4-amino-phenyl)-propionate Methyl 4-nitro-cinnamate, hydrogenated at 50C.
Rf value: 0.76 (silica gel; cyclohexane/ethyl acetate =
1:3) Example IV

Methyl 2-(n-butanesulphonylamino)-3-(4-nitrophenyl)-propionate .
25.9 g of methyl 2-amino-3-(4-nitrophenyl)-propionate hydrochloride are suspended in 100 ml of methylene chloride and mixed with 32 g of N-ethyl-diisopropylamine, whereupon the precipitate dissolves.
To the solution are added dropwise, at 8 to 15C, 17.1 g of n-butanesulphonylchloride in 20 ml of methylene chloride. After stirring for 16 hours at ambient temperature, 10 g of N-ethyl-diisopropylamine are added whilst cooling with ice and a further 8 g of n-butanesulphonylchloride are added dropwise and stirred for a further 2 hours at ambient temperature. The mixture is combined with ice water, the organic phase is washed successively with water, lN hydrochloric acid and water and concentrated by evaporation. The residue is purified over silica gel (eluant: methylene chloride).
Yield: 19.4 g (57% of theory), Melting point: 100-102C
Rf value: 0.38 (silica gel; cyclohexane/ethyl acetate =
6:4~

211~0'~

Example V

Methyl 2-amino-3-(4-nitrophenyl)-propionate-hydrochloride '- : ' : ,, 21 g of 4-nitro-phenylalanine are suspended in 250 ml of ~ -methanol and mixed with 10 ml of methanolic hydrochloric acid, whereupon the solid product dissolves. The mixture is left to stand for 60 hours at ambient temperature and evaporated down in vacuo. The product is used without any further purification. -Yield: 25.9 g (99% of theory), -~
Melting point: 206-208C (decomp.) Rf value: 0.67 (Reversed Phase Plate RP8; methanol/5% ~ ~
sodium chloride solution = 6:4) ; ~-, " , , The following compound is obtained analogously: - ~-(1) Methyl 3-(trans-4-amino-cyclohexyl)-propionate~
hydrochloride Melting point: above 200C ~ -ExamPle VI
: - ' 3-(trans-4-Amino-cyclohexyl)-propionic acid- ;~
hydrochloride ~
26 g of 3-(trans-4-acetamino-cyclohexyl)-propionic acid ` -are refluxed for 16 hours in 200 ml of 6N hydrochloric I acid. The mixture is evaporated to dryness in vacuo and --I evaporated down several more times after the addition of toluene and methanol. The residue is used directly.
Yield: 26 g (100~ o~ theory) `' ~;
~', 2il~3~

Example VII

3-(trans-4-Acetaminocyclohexyl)-propionic acid 112.7 g of 3-(4-acetaminophenyl)-propionic acid and 10 g of platinum dioxide are treated in 350 ml of glacial acetic acid at 60C with hydrogen at 5 bars pressure.
After 1.5 and 7 hours, the platinum dioxide is replaced with fresh. The entire reaction time is 10 hours. The mixture is evaporated to dryness ln vacuo and the residue is recrystallised from 1800 ml of acetone. The primary crystals are also recrystallised from 50 ml of 80% acetic acid.
Yield: 26 g (22.4% of theory), Melting point: 200-201C
Rf value: 0.30 (silica gel; methylene chloride/ethyl acetate/glacial acetic acid = 4:1:0.4) After evaporation and recrystallisation from 100 ml of water, 53.6 g (46% of theory) of cis-3-(4-acetamino-cyclohexyl)-propionic acid are obtained from the acetone mother liquor.

Example VIII -1-Benzyl-4-(3-carboxyphenyl)-3,4-dehydro-piperidine-hydrochloride 25 g of 1-benzyl-4-(3-bromo-phenyl)-3,4-dehydro-piperidine are dissolved in 300 ml of tetrahydrofuran.
The mixture is cooled to below -65C and at this temperature, within 30 minutes, 47.6 ml of a 1.6 molar solution of n-butyllithium in hexane are added dropwise.
The resulting mixture is stirred for a further hour and then a slow stream of carbon dioxide dried over conc. -~
sulphuric acid is passed over the reaction solution.
The temperature is first maintained for 1 hour at below -65C and then slowly allowed to rise to ambient - -- .. ,,....................................... :

` ~ 211103~

, temperature and the reaction mixture is left to stand at this temperature for 60 hours. It is then evaporated to dryness, the residue is taken up in 500 ml of ethyl --acetate and extracted with water. The aqueous phases -are concentrated by evaporation in vacuo, cooled in an ice bath and adjusted to pH 1 using 2N hydrochloric acid. The precipitated crystals are filtered off and washed with water.
Yield: 9 g (40~ of theory), Melting point: from 185C (decomp.) Rf value: 0.50 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) - -Example IX

1-Benzyl-4-(3-bromophenyl)-3,4-dehydro-piperidine -~ -' ':
29.6 g of 1-benzyl-4-(3-bromophenyl)-4-hydroxy-piperidine, 32.5 g of p-toluenesulphonic acid hydrate ~ -and 300 ml of toluene are heated for 2 hours using a ~-water separator. After cooling, the mixture is diluted with methylene chloride, ice water is added and the resulting mixture is made alkaline with 30% sodium hydroxide solution. The aqueous phase is extracted once -~
again with methylene chloride and the combined organic ~-phases are evaporated down ln vacuo.
Yield: 25.2 g (90% of theory), Rf value: 0.69 (silica gel; methylene chloride/methanol p = 100:2) Example X

1-Benzyl-4-(3-bromophenyl)-4-hydroxy-piperidine To a solution of 35.7 g of 1,3-dibromo-benzene in 200 ml of ether, 93.1 ml of a 1.6 molar solution of n-2111~3~

butyllithium in hexane are added dropwise over 25 minutes at a temperature below 0C. The mixture is stirred for a further 40 minutes and then, at a temperature below 10C, a solution of 28.2 g of freshly distilled l-benzyl-4-piperidone in 40 ml of ether is added dropwise. The mixture is stirred for a further 30 minutes at this temperature and finally for 1 hour at ambient temperature. 500 ml of saturated saline solution are added, the aqueous phase is extracted twice more with ethyl acetate, the organic phases are evaporated down in vacuo and the residue is purified by column chromatography over silica gel (eluant: methylene chloride/methanol = 100:2) Yield: 29.6 g (56% of theory), Rf value: 0.34 (silica gel; methylene chloride/methanol = 100:2 Example XI

3-(4-Acetaminophenyl)-propionic acid 155 g of methyl 3-(4-acetaminophenyl)-propionate are dissolved in 1000 ml of methanol, heated to 50C and mixed with 700 ml of 2N sodium hydroxide solution. The mixture is cooled to ambient temperature and stirred for ~ ' another 3 hours. It is then cooled in an ice bath, 750 ml of 2N hydrochloric acid are added and the mixture is stirred for another hour whilst cooling with ice.
The precipitate is filtered off and washed with a little ;
ice water.
Yield: 112.7 g (77.6% of theory), Melting point: 144-147C
Rf value: 0.25 (silica gel; methylene chloride/ethyl acetate/glacial acetic acid = 8:1:0.4) 2111~3~ `

Example XII
.
Methyl 3-(4-acetaminophenyl)-propionate `
138.4 g of methyl 3-(4-aminophenyl)-propionate are dissolved in 1000 ml of methylene chloride and 119 ml of triethylamine are added. The mixture is cooled to below 0C and within 35 minutes at 0 to 10C a solution of 58 ml of acetylchloride in 200 ml of methylene chloride is added dropwise. The resulting mixture is stirred for one hour at 0C, 300 ml of water are added, the organic -~-phase is extracted twice more with water and evaporated down in vacuo.
Yield: 155.5 g (91% of theory), Melting point: 118-120C
Rf value: 0.50 (silica gel; cyclohexane/ethyl acetate =
1:3) ~ ~
.- :

Example XIII

4-[4-[[4-[2-(Methoxycarbonyl)-ethyl]-phenyl]-iminomethyl]-phenyl]-l-trifluoroacetyl-piperidine 6.9 g of 4-(4-formylphenyl)-1-trifluoroacetyl-piperidine and 4.33 g of methyl 3-(4-aminophenyl)-propionate are refluxed for 5 hours in 50 ml of toluene using a water -~
separator. The mixture is evaporated down in vacuo and the product is used without any further purification.
Yield: 10.8 g (100% of theory), Rf value: 0.43 (silica gel; cyclohexane/ethyl acetate =
2:1) ::
~.', ~ .' 211103~

Example XIV

4-(4-Formylphenyl)-1-trifluoroacetyl-piperidine To a solution of 8.3 g of 4-phenyl-1-trifluoroacetyl-piperidine in 30 ml of methylene chloride, 7.8 ml of titanium tetrachloride are added dropwise at a temperature below 0C. After 10 minutes, 3.5 ml of dichloromethylmethylether are added dropwise over 40 minutes whilst the temperature is maintained below O-C.
The mixture is left to stand for 16 hours at ambient temperature, poured onto ice water and the aqueous phase is extracted several times with methylene chloride. The organic phases are evaporated down in vacuo and the residue is purified by column chromatography over silica gel (eluant: cyclohexane/ethyl acetate = 2:1) Yield: 6.9 g (75% of theory), Melting point: 76-77C
Rf value: 0.42 (silica gel; cyclohexane/ethyl acetate =
2:1) Example XV
~ ..
4-Phenyl-l-trifluoroacetyl-piperidine , ~ :
25 g of 4-phenyl-piperidine are dissolved in 250 ml of -~
methylene chloride, 29.8 ml of N-ethyl-diisopropylamine are added and the mixture is cooled to 0C. 24.1 ml of ~-trifluoroacetic acid anhydride are added dropwise to~the solution so that the temperature does not exceed 10C.
It is stirred for a further 30 minutes at 0C, allowed to warm to ambient temperature, 100 ml of water are added and the organic phase is washed twice more with water. The methylene chloride phase is evaporated down and the residue is used without further purification. ;~
Yield: 40 g (100% of theory), ''''~';"
: ~:

2ill û3~

Rf value: 0.90 (silica gel; cyclohexane/ethyl acetate =
1 : 1 ) Example XVI

4-(4-AminophenYl)-l-trifluoroacetyl-pi~eridine a) 4-Phenyl-l-trifluoroacetvl-PiPeridine To a solution of 125 g (0.775 Mol) of 4-phenyl-piperidine and 149 ml (0.775 Mol) of N,N-diisopropyl-ethylamine in 1300 ml of dichloromethane, 120.5 ml -~0.775 Mol) of trifluoroacetic acid anhydride are added dropwise at 5C, with stirring, over a period of 2 hours. The mixture is then stirred for a further hour whilst cooling with ice, left to stand overnight at ambient temperature and then diluted with 400 ml of water. The dichloromethane phase is separated off, washed twice with 400 ml of water, dried over sodium sulphate and evaporated to dryness ln vacuo.
Yield: 193 g (97% of theory) Yellow crystals ~`
Rf value: 0.88 (silica gel; cyclohexane/ethyl acetate =

b) 4-(4-Nitro~henyl)-l-trifluoroacetyl-Piperidine 80 g (0.311 Mol) of the 4-phenyl-1-trifluoroacetyl- -~
piperidine obtained in a) are dissolved in a mixture of 400 ml of glacial acetic acid and 200 ml of acetic anhydride. This solution is cooled to 10C in an ice bath and 1.6 g of sodium nitrite are added, with stirring, followed by the dropwise addition of 51.9 ml (0.311 Mol) of fuming nitric acid. The mixture is left to stand overnight at ambient temperature and then poured onto 1000 ml of water which contains 200 g of ice. The pH is adjusted to 8 using 8N sodium hydroxide solution within 4.5 hours, with cooling to prevent the .

` 21~1~3~
- ~2 -temperature exceeding 20C. The mixture is extracted with a total of 2000 ml of dichloromethane, the combined dichloromethane extracts are washed with 100 ml o~ 0.1 N
sodium hydroxide solution and then twice with water, dried over sodium sulphate and evaporated to dryness in vacuo. The residue is crystallised from ethyl acetate/cyclohexane.
Yield: 54.5 g (58% of theory) Yellow crystals Melting point: 100-102C

c) 4-(4-AminophenYl)-l-trifluoroacetvl-piperidine -The compound prepared in b) is dissolved in 700 ml of ethyl acetate and, after the addition of 7 g of palladium on charcoal (10~), it is hydrogenated at ambient temperature under 3 bars of hydrogen pressure.
The catalyst is filtered off and the ethyl acetate solution is evaporated to dryness ln vacuo.
Yield: 39.7 g (quantitative) Rf value: 0.25 (silica gel; cyclohexane:ethyl acetate =

:, ' - , ExamPle XVII

l-tert.Butyloxycarbonyl-4-[4-[[4-[2-(methoxycarbonyl)-ethvl~-piperidino~-methvll-~henvll-piperidine a) l-tert.Butyloxycarbonyl-4-(4-hydroxymethyl-phenyl)-Piperidine To a solution of 5 g (0.0164 Mol) of 1-tert.butyloxycarbonyl-4-(4-carboxy-phenyl)-piperidine and 1.66 g (0.0164 Mol = 2.28 ml) of triethylamine in 100 ml of tetrahydrofuran, a solution of 1.78 g (0.0164 Mol = 1.57) ml of ethylchloroformate in 10 ml of tetrahydrofuran is added dropwise with stirring at 5C
and the mixture is stirred at this temperature for a ~' 2111~3~
- ~3 -further hour. The triethylamine-hydrochloride precipitated is then suction filtered and washed with tetrahydrofuran. The combined tetrahydrofuran phases are then added dropwise, with stirring at 10 to 15C, into a solution of 1.55 g (0.041 Mol) of sodium borohydride. After stirring overnight at ambient temperature the mixture is evaporated to dryness in vacuo. The residue remaining is distributed between ethyl acetate and lN sodium hydroxide solution. The ethyl acetate phase is washed with water, dried over sodium sulphate and evaporated to dryness in vacuo. The residue remaining is crystallised from petroleum ether.
Yield: 4.05 g (84.7% of theory), Melting point: 78-80C

b) l-tert.Butyloxycarbonyl-4-(4-chloromethylphenyl)- ~ -PiPeridine A solution of 3.95 g (0.0136 Mol) of compound a) and -2.74 g (0.0271 Mol = 3.8 ml) of triethylamine in 80 ml -~ -~of dichloromethane are slowly combined, with stirring, -- ~
with 3.1 g (0.0271 Mol = 2.1 ml) of mesylchloride. ~-After addition is complete the mixture is left to stand -~
overnight and the clear solution is then evaporated to `~
dryness. The residue remaining is chromatographed over -~
silica gel using dichloromethane as eluant. ~ -Yield: 3.75 g (89% of theory), ~ ~
Melting point: 56-58C - ---Rf value: 0.47 (silica gel; dichloromethane) c) 1-tert.Butyloxycarbonyl-4-[4-[[4-[2- ~
(methoxycarbonyl)-ethyl]-piperidino]-methyl]-phenyl]- -Piperidine A mixture of 1.8 g (0.0058 Mol) of the compound prepared -~
under b), 1.44 g (0.007 Mol) of methyl piperidino-propionate hydrochloride, 1.42 g (1.95 ml = 0.014 Mol) of triethylamine and 3 g of sodium iodide in 150 ml of 2111~3~
- ~4 -chloroform are refluxed for 36 hours. The undissolved components are then removed by suction filtering. The filtrate is washed twice with water, dried over sodium sulphate and evaporated to dryness ln yacuo. The residue remaining is purified by chromatography over silica gel using methylene chloride/methanol (35:1) as eluant.
Yield: 2.05 g (79.8% of theory) Resin Rf value: 0.41 (silica gel; dichloromethane/methanol =
9.5:0.5) The following compound was prepared analogously:

(1) 1-tert.butyloxycarbonyl-4-[4-[[trans-4-[2- ~-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminomethyl]-phenyl]-piperidine --~::
,~
Prepared from l-tert.butyloxycarbonyl-4-(4-chloromethyl-phenyl)-piperidine and methyl trans-3-[4-amino-cyclohexane]-propionate Resin -Example XVIII

1-[tert.Butyloxycarbonyl]-4-[4-[[trans-4-methoxycarbonylcyclohexyl]-aminocarbonylamino]-phenyl]-piPeridineA solution of 1.2 g (0.0044 Mol) of 1-tert.-butyloxycarbonyl-4-[4-aminophenyl]-piperidine and 0.8 g (0.0044 Mol) of trans-[4-methoxycarbonylcyclohexyl]-isocyanate in 20 ml of dioxane is heated at 50~C for 2 hours. The mixture is then evaporated to dryness under reduced pressure and the solid residue is stirred with tert.butylmethylether. The remaining solid is suction filtered, washed with tert.butylmethylether and dried.

_~5_ 21103~j Rf value: 0.30 (silica gel; cyclohexane/ethyl acetate z 1 : 1 ) Example XIX

l-tert.Butyloxycarbonyl-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]~
piperidinol-piperidine a) l-tert.Butyloxycarbonyl-4-[t4-ethoxycarbonyl~- -~iperidinol-piperidine ~ .
A mixture of 24.9 g (0.1249 Mol) of N-tert.butyloxycarbonyl-4-piperidone, 19.3 ml (0.1249 Mol) of ethyl piperidino-4-carboxylate and 46.5 ml ~ -~
(0.1562 Mol) of titanium(IV)-isopropoxide is stirred for -~
one hour at ambient temperature. Then 170 ml of anhydrous ethanol followed by 5.3 g (0.0837 Mol) of sodium cyanoborohydride are added and the mixture is stirred for a further 20 hours. Thereafter, 34 ml of ~ -water are added, the inorganic solids obtained are removed by suction filtering and washed with ethanol.
The combined filtrates are evaporated to dryness. The residue remaining is dissolved in ethyl acetate. The insoluble inorganic solids are filtered off and the filtrate is evaporated to dryness in vacuo. The residue is purified by chromatography over a silica gel column using ethyl acetate/cyclohexane = 3:2 as eluant.
Yield: 32.9 g of an oily substance (77.3% of theory) Rf value: 0.36 (silica gel; ethyl acetate) b) l-tert.Butyloxycarbonyl-4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-pi~eridinol-~i~eridine 3.4 g (0.01 Mol) of the compound prepared in a) are stirred overnight in 20 ml of lN sodium hydroxide solution. After this time, complete saponification of ' :-``` 2111~3~

the ethylester had occurred. 20 ml of lN hydrochloric acid are added and the mixture is washed with ethyl acetate. The aqueous phase is evaporated to dryness in vacuo, the residue remaining is taken up twice in ethanol, evaporated down in vacuo and then dried at 80C
in vacuo. The residue is dissolved in 100 ml of dimethylformamide. This solution is combined with 2 ml (0.0102 Mol) of diphenyl-phosphorylchloride, cooled to -5C, 1.4 ml (0.0102 Mol) of triethylamine are added --with stirring and the mixture is stirred for a further hour at -5C. Then 2.26 g (0.0102 Mol) of methyl trans-3-[4-aminocyclohexyl]-propionate hydrochloride and 1.4 ml (0.0102 Mol) of triethylamine are added and the ~-mixture is stirred for a further 4 hours at ambient ~--temperature and then for one hour at 60C. In order to -complete the reaction, another 1 ml of diphenyl-phosphorylchloride and 1.4 ml of triethylamine are added and the mixture is stirred overnight at ambient temperature. It is then evaporated to dryness in vacuo, the r6!sidue is taken up in ethyl acetate, the ethyl acetate solution is washed twice with saturated sodium hydrocren carbonate solution and once with water and dried over sodium sulphate. After evaporation in vacuo, 4 g of a residue remain which are purified by column chromatography over silica gel, using dichloromethane/methanol = 20:1 and 10:1 as eluant. The residue is triturated with ether/petroleum ether, suction filtered and dried.
Yield: 2.98 g (62.1% of theory), Melting point: 182-184'C

' :~ ' .

" '~.~.

211~03 Example XX

4-~4-[[trans-4-[2-(Methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyll-Phenvll-l-benzyl-piperazine a) l-Benzyl-4-(4-cyanophenyl)-Piperazine A mixture of 26 g (0.2147 Mol) of 4-fluorobenzonitrile, 37.3 ml (0~2147 Mol) of N-benzylpiperazine and 36.7 ml (0.2147 Mol) of N-ethyl-diisopropylamine is heated to 140C for 8 hours. After cooling it is stirred into water and extracted with dichloromethane. The combined ~
dichloromethane phases are dried over sodium sulphate ~ ~-and evaporated down in vacuo. The residue remaining is crystallised from ether/petroleum ether. -Yield: 29.8 g (50.1% of theory), Melting point: 106-108C

b) l-Benzvl-4-(4-carboxY~henvl~-Piperazine 29.8 g (0.1074 Mol) of l-benzyl-4-(4-cyanophenyl)-piperazine are dissolved in 200 ml of ethyleneglycol.
After the addition of 48 g (0.8592 Mol) of potassium hydroxide the mixture is refluxed for 8 hours. The ethyleneglycol is then substantially distilled off in vacuo and the remaining oil is diluted with water.
After acidifying with acetic acid, the solid precipitate is suction filtered, washed with water and then with a little acetone and dried.
Yield: 31.4 g (98.7% of theory), Melting point: 225-227C (decomp.) c) 4-[4-[[trans-4-[2-(Methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-l-benzyl-piperazine . -To a solution of 1.5 g (0.051 Mol) of l-benzyl-4-(4-carboxyphenyl)-piperazine in 80 ml of dimethylformamide are added, at -5c and with stirring, 1 ml (0.0051 Mol) ¦ of diphenylphosphinic acid chloride and 0.7 ml ~;

21~ ~3~
` ` ~-.~EC-lY93 16:19 FRRNK 13. QEH~ ~ CU 071 240 07'76 P,0Z
, .

~O.O~l Mol) of tr~othyl~ine ~md th~ mixture i~ et~rr-d ror a ~urth-r hour a'c -5-C. Th~n 1.13 g ~O.OS1 Mol) o~
rothyl 3- (4-t~ ~inocyclohQxy~l -propio~?ltQ. ' hydrochlorid~ and O.~ ml (O.~Sl ~ol~ o~ trie~yl~ln~ .
ar ~dd~d ~nd ehe mixtur- i~ s~lrred o~rernlght ~t , :
~bi-n~ te,npsratur~. It is t~en ~r~porat~ to dryne~B
i,ll ~Q and th~ r~duo ~ pur~$ed by chro~a'cogr~p~y ;
over a ~lica g l colu~ lng dichlo ~ ~
I conta~n~ 2.5~ ~othanol a~ eluant. Th~ r~sldue re~alning -: - r' a ~ evapo~at~on o~ tha aluant iB trlturat-d with p-trol~u~ QthQr and ~uc~ion ril~rd.
Yî-ld: 1 . 04 g (44~ o~ ory), eltlng polnt: 188-189-C

~

4-t2-~tr~ns-4-~2-~ethoxycarbonyl-ethyl)-cyclohexy~
oxo-2,3-dihydro-~solndol-6-yl~-eyricina -:

, a) ~Qthyl 2-m thyl-s-~ri~luorc~thylsulphonylox~

; ~o a solution o~ 10 g ~60 mMol) o~ ~ethyl 3-hydroxy-6- ~
~athyl-benzoat~ in 40 ml o~ dry p~r~dln~ ~r~ add~d ~ -drop~ise, with 6tirr~ng, at -8 to 4~C, 18.2 ml (66 o~ ~rl~luoron-th~n-~ulphon~c acid anhydr~d~ wl~hin 35 I ~inut-~. A~ter the addition i~ Cempl~tQ th ~iXtNre iB
I ~tirr d ov sni~ht in an iCQ b~th and then pourQ~ onto I wat~r. It ~- xtracted wttn tert.butyl-methy1QthRr, th~
¦ coDbined eYtract~ ar~ wa~h~d ~ith dilut- hydrochlor~c : --I aaid ~nd th-n With watar, d~-d o~or sodium sulphato and -: ~
! ~v~porated to dryne~6 i~ v~uo. The orang--red oil :: ~
r-~inlng i0 puri~ied by colu~n chromatography over :~ :
lliQ gel, uslng cycloh-xan~/othyl ac-tat = ~:1 a~
el~ant.
Colourl~ss o~
Yield: 15.3 ~ (85.5$ of th~ory~

~: .
'., "-..,: ~

~92 ~ 3 5 Rf value: 0.60 (silica gel; ethyl acetate/cyclohexane =
9:1) ' ~' b) Methyl 2-bromomethyl-5-trifluoromethylsulphonyloxy-benzoate A mixture of 8.3 g (27.8 mMol) of the compound prepared under a), 5.3 g (30 mMol) of N-bromosuccinimide and 20 mg of 2,2'-azaisobutyronitrile in 100 ml of carbon tetrachloride is irradiated for one hour with a 300 W W -immersion lamp. The mixture is then cooled, the undissolved succinimide is filtered off and the filtrate is evaporated to dryness ln vacuo. The residue is purified by column chromatography over silica gel using cyclohexane/ethyl acetete = 9:1 as eluant.
Colourless oil.
Yield: 7.7 g (73.3% of theory), Rf value: 0.55 (silica gel; ethyl acetate/cyclohexane =
9 : 1 ) c) 2-[trans-4-(2-Methoxycarbonyl-ethyl)-cyclohexyl]-l-oxo-2,3-dihydro-6-trifluoromethylsulphonyloxy-isoindole To a solution of 2.2 g (10 mMol) of methyl trans-4-aminocyclohexylpropionate-hydrochloride and 3.9 g (5.1 ml = 30 mMol) of N,N-diisopropyl-ethylamine in 100 ml of dry dimethylformamide, a solution of 3.8 g (10 mMol) of the compound obtained in b) in 10 ml of dimethylformamide is added at ambient temperature with stirring and stirring is continued for a further 16 hours at ambient temperature. Then the mixture is evaporated down ln vacuo and the residue is distributed between water and dichloromethane. The organic phase is separated off, dried over sodium sulphate and evaporated to dryness ln vacuo. The solid residue is triturated with petroleum ether and suction filtered.
Yield: 1.9 g (42.2% of theory), Melting point: 104-105C
I

' _ 50 2111~3~
d) 4-[2-[trans-4-(2-Methoxycarbonyl-ethyl)-cyclohexyl]-l-oxo-2,3-dihYdro-isoindol-6-yll-pvridine A solution of 2.3 g (5.1 mMol) of the compound obtained in c), 1 g (8 mMol) of 4-pyridyl-boric acid, 0.58 g (0.5 mMol) of tetrakis-triphenylphosphine-palladium(0) and 3.3 ml (24 mMol) of triethylamine in 35 ml of dim~thylformamide is heated to 100C for 8 hours. After cooling, the mixture is added to 150 ml of water, the precipitate is suction filtered and washed with water.
After drying ln vacuo at 40C it is purified by column chromatography over silica gel, using dichloromethane/methanol = 19:1 as eluant.
Yield: 1.2 g (62.2% of theory), Melting point: 210-211C

ExamPle XXII

1-Benzyl-4-[2-[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-1-oxo-2,3-dihydro-isoindol-6-yl]-3,4 dehydro-piperidine '' .:'' .
a) 1-Benzyl-4-[2-[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-1-oxo-2,3-dihydro-isoindol-6-yl]-Pvridinium-bromide A mixture of 0.32 g (0.84 mMol) of 4-[2-[trans-4-(2- -~-(methoxycarbonyl)-ethyl)-cyclohexyl]-1-oxo-2,3-dihydro~
isoindole-pyridine, 0.2 ml (1.68 mMol) of benzylbromide ~-~
and 3 ml of acetonitrile is refluxed for half an hour, during which time a solid is precipitated. After ~
cooling and diluting with tert.butyl-methylether the ~ -mixture is suction filtered and the solid is dried at 40C in vacuo.
Yield: 0.4 g (86.7% of theory), Melting point: 252-255C ,~

` ~':-' : : :

07~ 1993 16:20 FRRNK a. DEHN ~ C0 071 Z40 0776 P.03 21~1~33~

- 51 _ b) l-Bon~yl-4-t2~ n~ 2- ~m tboxyaarbon~rl) -~th~rl]-oycloh ~yl] -1-o~2, 3-di hyd~o-i~olndo1-6-yll -3, ~-360 ~ ~0,66 ~o:l) of the c~ou~ obt~inad ~
u~pended in ;.0 ~1 o~ ~nol~ 38 ~q (1 ~olJ o~ iuu bo~n~ydrido ~ 4dl~d in 2 b~tche~ a~ ~lent t~p r~t~re, wl~ ~rr$n~ q!hQ lll~XtlaS' i~ d ~or a furth r 2 day- at ~blent t~ture an~ t~en ~t-r ic ~ed, thQ ~ 1 ~ct~ w~ sthyl a~etat-, the conblnod ~thyl ac-tat~ ~xtract~ a~ dr~-~l o~r ~phat~ an~ porat~d to dryn ~- ~ vaGuc~. The cry-tal~ r~lnlng ar~ dri d at 60-C ~B Y~. , Yleld~ 27a ~g ~86~6% of theory) Melting point: 142-1~,3-C ~ :~

.. . .

utyloxycarbonyl-3-~4-[ttr~ns-4-{2-(~ thoxyo~rbo~yl)-ethyl]-cyclohexylJ-~minoc~bonyl3- -~
ph~nyl]-pyrrolldin : ,., a) ~
124.g g ~1.2 ~ol) o~ xalonic ac~d arQ dis~olved ln 180 ~1 of pyr~d$ne. 16~.2 g ll ~ol) or ~-car~04eSh~xy-bensald hyde ~nd 8.52 g (O.l Mol) o~ piporldine ar~
add-d So thi~ olution and the ~u~p~ns~on thus obta~d ~8 heat-d eO SOO-C Scr 1~ hours. A~ter coolin~ ~o a~bient t mperatur the ~u~p-nsion i8 pou~-d into 800 ~1 o~ ic /w~ter ~nd aciq$ried with 200 ~1 concentr~d hydroohloric ac~d. ~he preci~ltat~ i~ auctlon rlltOr-d, w~h d care,~ully wlth w~t-r, d~ied, tr~tur~tod w~th aceton-r furthet ~uct~on ~lt-rod and dried.
Yi~ld: le,s~,o g ~89.72% o~ theory) ~el~ing po~nt~ 23~-241-C
, '.
' .
.,' .
T!~TFL F. 03 - 52 - 21~1~3~
b) 1-Benzyl-4-[2-[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-1-oxo-2,3-dihydro-isoindol-6-yl]-3,4-dehydro-piPeridine 360 mg (0.66 mMol) of the compound obtained in a) are suspended in 10 ml of ethanol. 38 mg (1 mMol) of sodium borohydride are added in 2 batches at ambient temperature, with stirring. The mixture is stirred for a further 2 days at ambient temperature and then water is added, the mixture is extracted with ethyl acetate, the combined ethyl acetate extracts are dried over sodium sulphate and evaporated to dryness in vacuo. The crystals remaining are dried at 60C in vacuo.
Yield: 270 mg (86.6% of theory), Melting point: 142-143C
- ': ,- .: -:-:

Exam~le XXIII ~ --l-tert.butyloxycarbonyl-3-(4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-pyrrolidine '::~'~ ;:. .
::
a) 4-methoxvcarbonyl-trans-cinnamic acid 124.9 g (1.2 Mol) of malonic acid are dissolved in 180 ;~
ml of pyridine. 164.2 g (1 Mol) of 4-carbomethoxy~
benzaldehyde and 8.52 g (0.1 Mol) of piperidine are -~
added to this solution and the suspension thus obtained is heated to 100C for 1~ hours. After cooling to ambient temperature the suspension is poured into 800 ml of ice/water and acidified with 200 ml concentrated hydrochloric acid. The precipitate is suction filtered, washed carefully with water, dried, triturated with acetone, further suction filtered and dried.
Yield: 185.0 g (89.72% of theory) Melting point: 329-241C

- 53 - 2111~3~
b) methyl 4-methoxycarbonyl-trans-cinnamate A mixture of 184.8 g (0.896 Mol) of 4-methoxycarbonyl-trans-cinnamic acid, 10 ml of sulphuric acid and 3 l of methanol is refluxed for 18 hours. After cooling with an ice bath the resulting white crystals are suction filtered, washed with methanol and dried.
Yield: 175.9 g (89.2% of theory) Melting point: 121-123C

c) methyl 3-(4-methoxycarbonyl-phenyl)-3-(nitro- ~ -methvl3-~ro~ionate To a suspension of 22 g (0.1 Mol) of methyl 4-methoxycarbonyl-trans-cinnamate in 59 g (0.966 Nol) = 52 -~-ml of nitromethane, 2.4 g (0.021 Mol) ` 2.6 ml of 1,1,3,3-tetramethylguanidine are added. After heating at 70C for 5 hours, the reaction mixture is cooled and evaporated to dryness in vacuo. The residue is divided between ethyl acetate and 2 N hydrochloric a~id. The organic phase is washed with water, dried and evaporated to dryness in vacuo. The remaining crude brown oil is chromatographed over silica gel with cyclohexane/ethyl acetate (7:3 to 3:2).
Yield: 20.~ g of a light yellow oil (74% of theory) Rf value: 0.52 (silica gel; cyclohexane/ethyl acetate =
3:2) d) 3-(4-methoxycarbonYl-phenyl)-~yrrolidin-5-one 20.3 g (0.72 Mol) of 3-(4-methoxycarbonyl-phenyl)-3-(nitromethyl)-propionic acid are hydrogenated in 200 ml of methanol in the presence of 2 g of Raney Nickel for 7 hours at 60C under a pressure of 3 bar. The catalyst is then removed by suction filtering and the filtrate is evaporated to dryness in vacuo. The remaining crude, yellow material is triturated with dichloromethane. The resulting precipitate is suction filtered, washed with dichloromethane and dried.
Yield: 11.2 g (70.9% of theory) - 54 211~33~
.
Melting point: 154-156C

e) 3-(4-methoxycarbonyl-phenyl)-pyrrolidine-hydrochloride -16.5 g t274 mMol) = 15.7 ml of glacial acetic acid are slowly added to a solution of 6 g (27 mMol) of 3-(4-methoxycarbonyl-phenyl)-pyrrolidin-5-one and 10.4 g (274 mMol) of sodium borohydride in 120 ml of dioxane with stirring and at a temperature of 10 to 15C. The resulting mixture is refluxed for 7 hours. After -~
stirring overnight at ambient temperature a further ~- -quantity of 5.2 g of sodium borohydride is added followed by 7.9 ml of glacial acetic acid in 30 ml of -dioxane. After refluxing for a further 6 hours, the --solution is evaporated to a small volume, diluted with - ~
500 ml of water and extracted with dichloromethane. The - ~-organic phase is washed with water, dried and evaporated to a small volume. The resulting solution is treated ~-~
with hydrogen chloride and evaporated to dryness.
Yield: 6.2 g of a colourless oil (93.9% of theory) -Rf value: 0.63 tReversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) f) l-tert.butyloxycarbonyl-3-(4-methoxycarbonyl- ~-~
~henvl)-Pyrrolidine 9.0 g (41.17 mMol) of di-tert.butyl dicarbonate are added to 6.2 g (25.6 mMol) of 3-(4-methoxycarbonyl- ~
phenyl)-pyrrolidine-hydrochloride dissolved in a mixture ~-of 40 ml dioxane, 20 ml water and 14.3 ml triethylamine after cooling with ice. After stirring overnight the solution is evaporated to dryness. The remaining oily substance is divided between dichloromethane and water.
The organic phase is washed with water, dried and evaporated to dryness. The remaining oily substance is chromatographed over silica gel with cyclohexane/ethyl acetate (4~
Yield: 4.8 g of a light yellow oil (61.5% of theory) , 2 1 ~

Rf value: 0.62 (silica gel; cyclohexane/ethyl acetate -3:2) g) 1-tert.butyloxycarbonyl-3-(4-carboxyphenyl)-yrrolidine A mixture of 4.7 g (15.4 mMol) of 1-tert.butyloxycarbonyl-3-(4-methoxycarbonyl-phenyl)-pyrrolidine, 15.4 ml of 2 N sodium hydroxide, 100 ml of tetrahydrofuran and 3.3 ml of water is stirred for 24 hours at ambient temperature. A second quantity of 15.4 ml of 2 N sodium hydroxide is then added and the solution is heated to 50C for 7 hours. After cooling to ambient temperature 31 ml of 2 N hydrochloric acid and aqueous citric acid are added to give a pH of 3.
The resulting solution is evaporated to a small volume.
The resulting colourless precipitate is suction filtered, washed with water and dried.
Yield: 3.8 g (84.4% of theory) Melting point: 145-147C

h) 1-tert.butyloxycarbonyl-3-[4-C[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-Phenyll-~Yrrolidine A mixture of 3.75 g (12.87 mMol) of 1-tert.butyloxy-carbonyl-3-(4-carboxyphenyl)-pyrrolidine, 3.1 g (13.86 mMol) of methyl trans-(4-amino-cyclohexyl)-propionate, 7.9 g (77.67 mMol) = 10.8 ml of triethylamine and 4.45 g (13.86 mMol) of 2-[(lH)-benzotriazol-l-yl]-1,1,3,3-tetramethyluronium-tetra-fluoroborate in 100 ml of absolute dimethylformamide is stirred for 2 hours at ambient temperature. After diluting the suspension with 250 ml of water, the resulting colourless precipitate is suction filtered, washed with water and dried.
Yield: 5.75 g (100% of theory) Melting point: 99-103C

56 2111~3~
, ~
Example XXIV

1-tert.butyloxycarbonyl-3-[4-[[trans-4-(2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]- ~
phenyll-3-methvl-pYrrolidine ~-' '-' a) 2-(4-methoxvcarbonyl-phenyl)-pronionitrile 1.3 g of sodium hydride (5S-62% in oil) are added to a solution of 5.3 g (30.25 mMol) of 4-methoxycarbonyl- ~
phenyl-acetonitrile in 50 ml of dimethylformamide whilst -cooling with ice. After ten minutes 4.3 g (30.25 mMol~ , = l.9 ml of methyl iodide are added dropwise with cooling maintained. The resulting suspension is stirred for 1~ hours, diluted with water and evaporated to a -~
small volume. The remaining solution is diluted again -~
with water, acidified with citric acid and extracted ~ - -with ethyl acetate. The combined organic phase is -~
washed with water, dried and evaporated to dryness in vacuo. The remaining oily substance is chromatographed over silica gel with cyclohexane/ethyl a~etate (17:3). --~
Yield: 32 g of a light yellow oil (47.1% of theory) Rf value: 0.5 (silica, gel, cyclohexane/ethyl acetate =
7:3) b) methyl 3-cyano-3-(4-methoxycarbonyl-phenyl)-butyrate 0.72 g of sodium hydride (55-65% in oil) ars added to a solution of 3.1 g (16.38 mMol) of 2-(4-methoxycarbonyl- -phenyl)-propionitrile in 50 ml of dimethylformamide whilst cooling with ice. After 15 minutes 2.5 g (16.4 mMol) = 1.55 ml of methyl bromoacetate is added dropwise whilst cooling is maintained. The resulting suspension is stirred for 2~ hours, diluted with water and evaporated to a small volume. The resulting solution is diluted again with water, acidified with citric acid and extracted with ethyl acetate. The combined organic -phase is washed with water, dried and evaporated to 211103~

dryness in vacuo. The remaining oily substance is chromatographed over silica gel with cyclohexane/ethyl acetate (7:3).
Yield: 3.6 g (83.7% of theory) Melting point: 75-77C

c) 3-(4-methoxycarbonyl-phenyl)-3-methyl-pyrrolidin-5-one A solution of 3.3 g (12.6 mMol) of methyl 3-cyano-3-(4-methoxycarbonyl-phenyl)-butyrate in 100 ml of methanol is acidified with 12 ml of methanolic hydrochloric acid and hydrogenated in the presence of 1 g of palladium on charcoal (10%), at a pressure of 3 bar for 6 hours at ambient temperature. After removing the catalyst by suction filtering the filtrate is evaporated to dryness in vacuo. The remaining solid is dissolved in ethyl acetate and the organic phase is extracted with water.
The aqueous phase is adjusted to a pH >7 by adding a solution of potassium carbonate and then extracted with ethyl acetate. The organic phase is dried and evaporated to dryness in vacuo. The remaining solid is triturated with ethyl acetate, suction filtered, washed with ethyl acetate and dried.
Yield: 2.2 g (75.9% of theory) Melting point: 188-189C

d) 3-(4-methoxycarbonyl-phenyl)-3-methylpyrrolidine-hvdrochloride 5.6 g (92.5 mMol) = 5.3 ml of glacial acetic acid are -slowly added to a solution of 2.15 g (9.22 mMol) of 3-(4-methoxycarbonyl-phenyl)-3-methylpyrrolidine-5-one and 3.5 g (92.5 mMol) of sodium borohydride in 60 ml of dioxane with stirring and at temperature of 10 to 15C. ~ ~
The mixture is refluxed for 6 hours. After stirring ~; -overnight at ambient temperature a further 1.8 g of sodium borohydride is added followed by 2.7 ml of glacial acetic acid in 10 ml of dioxane. After 2 ~ 3 ~

refluxing for a further 7 hours the solution is evaporated to a small volume, diluted with 300 ml of water and extracted with dichloromethane. The ; -dichloromethane phase is washed with water, dried and evaporated to a small volume. The resulting solution is treated with hydrogen chloride and evaporated to dryness.
Yield: 1.14 g of a colourless oil (48.6% of theory) ~ -Rf value: 0.5 (Reversed Phase Plate RP8; methanol/5% ;
sodium chloride solution = 6:7) e) 1-tert.butyloxycarbonyl-3-(4-methoxycarbonyl-Phenyl)-3-methyl-Pvrrolidine 1.6 g (7.15 mMol) of di-tert.butyl dicarbonate are added to a solution of 1.14 g (4.46 mMol) of 3-(4-methoxycarbonyl-phenyl)-3-methyl-pyrrolidine-hydrochloride in a mixture of 8 ml dioxane, 4 ml water and 2.5 ml triethylamine after cooling with ice. After stirring for 2 hours the solution is evaporated to dryness and the remaining oily substance is triturated between dichloromethane and water. The organic phase is washed with water, dried and evaporated to dryness.
Yield: 1.18 g of a colourless oil (83.12% of theory) Rf value: 0.62 (silica gel, cyclohexane/ethyl acetate =
3:2) f) l-tert.butyloxycarbonyl-3-(4-carboxyphenyl)-3-methvl-Pyrrolidine A mixture of 1.1 g (3.44 mMol) of l-tert.butyloxy- ~-carbonyl-3-(4-methoxycarbonyl-phenyl)-3-methyl-pyrrolidine, 7 ml of 2 N sodium hydroxide, 20 ml tetrahydrofuran and 1 ml water is stirred for 3 days.
After this time 7 ml of 2 N hydrochloric acid and citric acid are added to give a pH of 2. The resulting solution is evaporated to a small volume and extracted ~ -with dichloromethane. The organic extract is washed with water, dried and evaporated to dryness. The ~`~

2111~3~
~ig remaining oily substance is chromatographed over silica gel with cyclohexane/ethyl acetate (4:1 to 1:1).
Yield: 600 mg of a light yellow oil (51.1% of theory) Rf value: 0.5 (silica gel; cyclohexane/ethyl acetate =
3:2) g) l-tert.butyloxycarbonyl-3-[4[[trans~4-(2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl~-phenyll-1-methyl-pyrrolidine A mixture of 0.57 g (1.87 mMol) of 1-tert.butyloxy-carbonyl-3-(4-carboxyphenyl)-3-methyl-pyrrolidine, 0.445 g (2.01 mMol) of methyl trans-(4-amino-cyclohexyl)-propionate, 1.14 g (0.113 mMol) = 1.56 ml of triethylamine and 0.645 g (2 mMol) of 2-[(lH)-benzotriazol-l-yl]-1,1,3,3-tetramethyluronium-tetrafluoroborate in 15 ml of absolute dimethylformamide is stirred for 2 hours at ambient temperature. The resulting suspension is diluted with water and evaporated to dryness. The residue is divided between ethyl acetate and a diluted potassium hydrogencarbonate ~-solution. The organic phase is washed with water, dried and evaporated to dryness. The remaining oily substance is chromatographed over silica gel with cyclohexane/ -~
ethyl acetate = 4:1.
Yield: 300 mg of a colourless oil (37.5% of theory).
Rf value: 0.31 (silica gel; cyclohexane/ethyl acetate = --~
3:2) ~
: ~ ' '~

-`:` 211103~

Preparation of the end compounds:

Exam~le 1 1-tert.Butyloxycarbonyl-4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine A solution of 0.76 g of 1-tert.butyloxycarbonyl-4-(4-carboxyphenyl)-piperidine, 0.90 g of 2-[(lH)-benzotriazol-1-yl]-1,1,3,3-tetramethyluronium-tetrafluoroborate, 0.55 g of mathyl 3-(trans-4-amino-cyclohexyl)-propionate-hydrochloride, 0.38 g of 1-hydroxy-(lH)-benzotriazole and 0.67 g of N-methyl-morpholine in 50 ml of dimethylformamide is stirred for 16 hours at ambient temperature. The solvent is removed under reduced pressure. 200 ml of water are added to the residue and the aqueous phase is extracted with ethyl acetate. The organic phase is dried over sodium sulphate and filtered and the solvent is removed under reduced pressure. 1.8 g of a solid are obtained which is chromatographed with methylene chloride/methanol (9:1) over silica gel.
Yield: 1.15 g (98% of theory), Melting point: sintering from 169C
Rf value: 0.60 (sili~a gel; methylene chloride/methanol =
9 : 1 ) ,. :

The following compounds are obtained analogously:

(1) l~tert.butyloxycarbonyl-4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl~-phenyl]-piperidine Melting point: 157-162~C
Rf value: 0.53 (silica gel; cyclohexane/ethyl acetate =
1: 1 ) (2) 4-[4-[[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl~-phenyl]-l-tert.butyloxycarbonyl-piperidine Rf value: 0.41 (silica gel; cyclohexane/ethyl acetate =
1 : 1 ) Mass spectrum: (M+Na)+ = 624 (3) 4-[4-L[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-quinuclidine (4) 4-[4-[[trans-4-[2-methoxycarbonyl~-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-pyridine (5) 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-piperidino]-pyridine (6) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-piperidino]-pyridine ~:.

(7) 4-[4-[[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]- :
piperidino]-pyridine ::
(8) 4-[4-[[4-[2-(n-hexanoylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-piperidino]-pyridine (9) 4-[4-[[trans-4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl~
piperidino]-pyridine ~' (10) 4-[4-[[trans-4-[2-(n-hexanoylamino)-2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]- ~:
piperidino]-pyridine -(11) 1-tert.butyloxycarbonyl-4-[4-[[trans-4-(methoxycarbonyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine -`` 21~103~

Melting point: 197-200C
Rf value: 0.20 (silica gel; methylene chloride/methanol =
20: 1) (12) 4-[4-[[4-(tert.butyloxycarbonyl-methyloxy)-phenyl]- , carbonylamino]-phenyl]-l-trifluoroacetyl-piperidine Prepared from 4-[4-amino-phenyl]-1-trifluoroacetyl-piperidine and 4-[tert.butyloxycarbonyl-methyloxy]-benzoic acid Melting point: 177-178VC

,Example 2 -;

4-[4-[[trans-4-[ 2 - (Methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride A mixture of 1.1 g of 1-tert.butyloxycarbonyl-4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine, 40 ml of dioxane and 40 ml of ethereal hydrochloric acid is stirred for 5 -'~
hours at ambient temperature, during which tims an oil is precipitated. The mixture of solvents is decanted off and the remaining oil is triturated with ether. The ,'",~,i solids produced are suction filtered and dried.
Yield: 0.87 g (91% of theory), Melting point: 225-232C
Rf value: 0.53 (silica gel; methylene chloride/methanol/ -~
conc. ammonia = 4:1:0.25) -, Mass spectrum: M+ = 372 The following compounds are obtained analogously:

(1) 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: 222-225C
Rf value: 0.54 (silica gel; methylene chloride/
, methanol/conc. ammonia = 4:1:0.25) '' I Mass spectrum: M+ = 366 211103!3 (2) 4-[4-[[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: sintering from 70C
Rf value: 0.63 (silica gel; methylene chloride/
methanol/conc. ammonia = 4:1:0.25) Mass spectrum: (M+H)' = 502 (3) 4-[4-[[trans-4-[2-acetamino-2-(methoxycarbonyl)- :
ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine- -hydrochloride (4) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-oxymethyl]-phenyl]-piperidine-hydrochloride (5) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]- -cyclohexyl]-methyloxy]-phenyl]-piperidine-hydrochloride '-~

(6) 4-[4-[[trans-4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]- :~
phenyl]-piperidine-hydrochloride ~--:

(7) 4-[4-[[trans-4-[2-(methanesulphonylamino)-2- -~-~
(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]~
phenyl]-piperidine-hydrochloride (8) 4-[4-[[trans-4-[2-(n-hexanoylamino)-2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (9) 4-[4-[[trans-4-[2-~methoxycarbonyl)-propyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (10) 4-[4-[N-[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-N-methyl-aminocarbonyl]-phenyl]-piperidine-hydrochloride 2111~3~

(11) 4-[4-[[trans-4-[2-(methoxycarbonyl)~ethyl]-cyclohexyl]-carbonylamino]-phenyl]-piperidine hydrochloride (12) 4-[4-[[trans-4-[3-(methoxycarbonyl)-propyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (13) 4-[4-[[trans-4-(methoxycarbonylmethyl)-cyclohexyl]-aminocarbonyl]-phenyl~-piperidine-hydrochloride Melting point: >250C --Rf value: 0.4 (Reversed Phase Plate RP8; methanol/5% ~
sodium chloride solution = 6:4) ::
(14) 4-[4-[[4-[3-(methoxycarbonyl)-propyl]-piperidino]~
carbonyl]-phenyl]-piperidine-hydrochloride ;~ ~
(15) 4-[4-[[4-[4-(methoxycarbonyl)-butyl]-piperidino]- -carbonyl]-phenyl]-piperidine-hydrochloride : ~' (16) 4-[4-[[4-[3-(methoxycarbonyl)-propyl]-piperazino]- ~ ~-carbonyl]-phenyl]-piperidine-dihydrochloride ~; :
(17) 4-[4-[[1-[2-(methoxycarbonyl)-ethyl]-4-piperidinyl]-aminocarbonyl]-phenyl]-piperidine-dihydrochloride -.
(18) 4-[4-[[4-[3-(methoxycarbonyl)-propyl]-3-oxo- ~:
piperazino]-carbonyl]-phenyl]-piperidine-hydrochloride ~-(19) 1-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperazine-hydrochloride Melting point: 190-192C
(20) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-3,4-dehydro-21~103~
~ 65 -piperidine-hydrochloride (21) 4-~4-[[trans-4-[2-(methoxycarbonyl)-n-octyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (22) 4-[4-[[trans-4-[2-(benzylsulphonylamino)-2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (23) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-4-methyl-piperidine- -hydrochloride (24) 4-cyano-4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]- ~
cyclohexyl]-aminocarbonyl]-phenyl]-piperidine- 1~ -hydrochloride (25) 4-aminocarbonyl-4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine.-hydrochloride (26) 4-(methoxycarbonyl)-4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (27) 3-[4-[[trans-4-[2-methoxycarbonyl)-ethyl]- ~:
cyclohexyl]-aminocarbonyl~-phenyl]-n-propylamine- -~
hydrochloride (28) 5-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-n-pentylamine-hydrochloride (29) 5-[4-[[trans-4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-n-pentylamine-hydrochloride 2 ~ 3 3 '~
- ~6 -(30) 5-[4-[[trans-4-[2-(n-hexanoylamino)-2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-n-pentylamine-hydrochloride (31) 1-[5-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-pyridin-2-yl]-piperazine-dihydrochloride (32) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-3-methyl-phenyl]-piperidine-hydrochloride : :
(33) 4-[3-methoxy-4-[[trans-4-[2-(methoxycarbonyl)- : -- :ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine- -hydrochloride -:
(34) 4-[4-[[trans-4-[2-amino-2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-dihydrochloride (35) 4-[4-[[cis-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (36) 4-[4-[[cis-4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (37) 4-[4-[[4-[2-(n-hexanoylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (38) 4-~4-[[trans-4-(methoxycarbonylmethoxy)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine- -~
hydrochloride (39) 4-[3-[[4-[2-(benzylsulphonylamino)-2- ~ :

' ~
` 211103~

(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (40) 4-[3-[[4-[2-(n-hexanoylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (41) 4-[4-[[4-[2-(benzylsulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl~-phenyl]- - :
piperidine-hydrochloride (42) 4-[3-fluoro-4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (43) 4-[3-ethoxy-4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (44) 1-[2-bromo-4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl~-piperazine-hydrochloride . :
(45) 4-[3-chloro-4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (46) 4-[4-[[2-bromo-4-[2-(methoxycarbonyl)-ethyl]- :~
phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (47) 4-[4-[[2-methoxy-4-[2-(methoxycarbonyl)-ethyl]- : ~
phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride ::
(48) 4-[4-[[trans-4-~2-(methoxycarbonyl)-ethyl]- :
cyclohexyl]-aminocarbonyl]-2-methylthio-phenyl]-piperazine-hydrochloride (49) 1-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl~-cyclohexyl]-aminocarbonyl]-2-methylsulphonyl-phenyl]-piperazine-hydrochloride (50) 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-2-methyl- ;
phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (51) 4-[4-~[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-sulphonylamino3-phenyl]-piperidine-hydrochloride -(52) 4-[4-[[4-[2-(methoxycarbonyl)-ethenyl]-phenyl]- ~
aminocarbonyl]-phenyl]-piperidine-hydrochloride -(53) 4-[4-[[trans-4-(methoxycarbonyl)-cyclohexyl]- -aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: 260-265C
Rf value: 0.39 (æilica gel; methylene chloride/
methanol/conc. ammonia = 4:1:0.25) (54) 4-[4-[[4-[2-(methoxycarbonyl~-ethyl]-piperidino]-methyl]-phenyl]-piperidine-dihydrochloride Yield: 0.44 g (88 % of theory), resin;
Rf value: 0.65 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) H-NMR-Spectrum (200 MHz, DMS0-d6); signals at ppm:
1.2-1.6 (m, 4H); 1.6-2.05 (m, 6+1H); 2.25-2.4 (t, 2H);
2.8-3.1 (m, 4 +lH); 3.3-3.55 (t, 4H); 3.6 (s, 3H);
4.2 (d, 2H); 7.3 (d, 2H); 7.5 (d, 2H); 8.4-8.9 (m, 2H); -~
9.9 (s, lH) (55) 1-[4-[[4-(methoxycarbonylmethoxy)-phenyl]-carbonylamino]-phenyl]-piperazine-hydrochloride (56) 4-[4-[[4-[2-(methoxycarbonyl)-ethenyl]-phenyl]-carbonylamino]-phenyl]-piperazine-hydrochloride (57) 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-I

'1 21~10~

carbonylamino]-phenyl]-piperidine-hydrochloride (58~ 4-[4-[[trans-4-(methoxycarbonyl)-cyclohexyl]-methylaminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: >250C
Rf value: 0.43 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) (59) 4-[4-[[trans-4-(methoxycarbonyl)-cyclohexyl]-methylaminocarbonyl]-phenyl]-piperidine-hydrochloride R~ value: 0.43 (Reversed Phase Plate ~P8; methanol/5% ~-sodium chloride solution = 6:4) (60) 4-[4-[~trans-4-(methoxycarbonyl)-cyclohexyl]-aminocarbonylamino]-phenyl]-piperidine-hydrochloride (61) 4-[4-[[trans-4-(methoxycarbonylmethoxy)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride Rf value: 0.6 (Reversed Phase Plate RP8; methanol/5% -~
sodium chloride solution = 6:4) - -(62) 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-piperidinyl]-carbonyl]-phenyl]-piperidine-hydrochloride -Instead of hydrochloric acid, trifluoroacetic acid was used. -~-Melting point: 177-179C (decomp.) -(63) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-piperidino]-piperidine-dihydrochloride Instead of hydrochloric acid, trifluoroacetic acid was used. -~
Yield: 1.98 g (75.4 % of theory), Melting point: 302-303C (decomp.) .,~.

. , , , " .:, -, , ., , ~: ,, ,, . . ~ , .

- 211103~

Example 3 4-[4-[[trans-4-(2-Carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride 0.41 g of 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride are stirred with 80 ml of 6N hydrochloric acid for 4 hours at ambient temperature. The precipitate formed is filtered off and washed with water.
Yield: 0.33 g (84% of theory), Melting point: 280-285C
Rf value: 0.07 (silica gel; methylene chloride/methanol/
conc. ammonia = 4:1:0.25) Mass spectrum: M+ = 358 The following compounds are obtained analogously:

(1) 4-[4-[[4-(2-carboxyethyl)-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride ~ -Melting point: 290-293C
Rf value: 0.11 (silica gel; methylene chloride/
methanol/conc. ammonia = 4:1:0.25) Mass spectrum: M+ = 352 .--.-.- ' (2) 4-[4-[[4-(2-carboxyethyl)-phenyl]-aminocarbonyl]~
phenyl]-1-methyl-piperidine-hydrochloride Saponification is carried out with lithium hydroxide in a 5:4 mixture of tetrahydrofuran and water, lN ~ ~-hydrochloric acid is added and the tetrahydrofuran is evaporated off in vacuo.
Melting point: above 300C
Rf value: 0.13 (silica gel; methylene chloride/
¦ methanol/conc. ammonia = 4:1:0.25) l Mass spectrum: M+ = 366 -- 71 - 2 1 ~ ~ ~ 3 ~
(3) 4-[4-[[4-[2-(n-butanesulphonylamino)-2-carboxy-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: 130C (sintering from 120C) Rf value: 0.15 (silica gel; methylene chloride/methanol/conc. ammonia = 4:1:0.25) Mass spectrum: (M-H) = 486 (4~ 4-[3-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride -~
A 1:1:0.5 mixture of water, conc. hydrochloric acid and glacial acetic acid is used.
Rf value: 0.6Q (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) Mass spectrum: M' = 358 ;~

(5) 4-[3-[[4-(2-carboxyethyl)-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride A 1:1:1 mixture of water, conc. hydrochloric acid and - -glacial acetic acid is used. -- --Rf value: 0.43 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) Calc. x HCl x 1.3 H20: C 60.47 H 6.67 N 6.71 Found : 60.25 6.77 6.65 ~
''' ~'~' (6) 4-[3-[[4-[2-(n-butanesulphonylamino)-2-carboxy- -~-~
ethyl~-phenyl]-aminocarbonylJ-phenyl]-piperidine-hydrochloride The same procedure is used as in (4). ~-Melting point: over 200C -Rf value: 0.60 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) Mass spectrum: (M+H)f = 488 (7) 4-[4-[[trans-4-(2-acetamino-2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride '~':
` ' ~ .

- 72 - 21~103~
(8) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-1-isopropyl-piperidine-hydrochloride (9) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-oxymethyl]-phenyl]-piperidine-hydrochloride (10) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-methyloxy]-phenyl]-piperidine-hydrochloride (11) 4-[4-[[trans-4-[2-(n-butanesulphonylamino)-2-carboxyethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (12) 4-[4-[[trans-4-[2-carboxy-2-(methanesulphonyl-amino)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (13) 4-[4-[[trans-4-[2-carboxy-2-(n-hexanoylamino)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (14) 4-[4-[[trans-4-(2-carboxypropyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (15) 4-[4-[N-[trans-4-(2-carboxyethyl)-cyclohexyl]-N-methyl-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: 245-247C

~16) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-carbonylamino]-phenyl]-piperidine-hydrochloride (17) 4-[4-[[trans-4-(3-carboxypropyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (18) 4-[4-[(trans-4-carboxymethyl-cyclohexyl)-aminocarbonyl]-phenyl]-piperidine-hydrochloride 211103~

Melting point: >250C
Rf value: 0.5 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) (19) 4-[4-[[4~(3-carboxypropyl)-piperidino]-carbonyl]-phenyl]-piperidine-hydrochloride (20) 4-[4-[[4-(4-carboxybutyl)-piperidino]-carbonyl]-phenyl]-piperidine-hydrochloride (21) 4-[4-t[4-(3-carboxypropyl)-piperazino]-carbonyl]-phenyl]-piperidine-dihydrochloride (22) 4-[4-[[1-(2-carboxyethyl)-4-piperidinyl]-aminocarbonyl]-phenyl]-piperidine-dihydrochloride (23) 4-[4-[[4-(3-carboxypropyl)-3-oxo-piperazino]- -carbonyl]-phenyl]-piperidine-hydrochloride :~

(24) 1-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperazine-hydrochloride ,~
Melting point: 300-302C (decomp.) (25) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-quinuclidine-hydrochloride : - ::
(26) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-pyridine-hydrochloride -~

(27) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-3,4-dehydro-piperidine- -hydrochloride (28) 4-[4-[[trans-4-(2-carboxy-n-octyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride 'I ., .
~' .

211103~

(29) 4-[4-[[trans-4-[(2-benzylsulphonylamino)-2-carboxy-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (30) 4-[4-[[trans-4-t2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-4-methyl-piperidine-hydrochloride (31) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-4-cyano-piperidine-hydrochloride (32) 4-aminocarbonyl-4-[4-~[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (33) 4-carboxy-4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (34) 3-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-n-propylamine-hydrochloride (35) 5-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-n-pentylamine-hydrochloride (36) 5-[4-[[trans-4-[2-(n-butanesulphonylamino~-2-carboxyethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-n-pentylamine-hydrochloride (37) 5-[4-[[trans-4-[2-carboxy-2-(n-hexanoylamino)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-n-pentylamine-~ -, hydrochloride (38) 1-[5-[[trans-4-(2-carboxyethyl)-cyclohexyl]- ;~ ::
aminocarbonyl]-pyridin-2-yl]-piperazine-dihydrochloride~:

(39) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-3-methyl-phenyl]-piperidine-hydrochloride - 75 - 2~ 3~
(40) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-3-methoxy-phenyl]-piperidine-hydrochloride The same procedure is used as in (2) (41) 4-[4-[[trans-4-(2-amino-2-carboxyethyl)- ~-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-dihydrochloride -(42) 4-[4-[[cis-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (43) 4-[4-[[cis-4-[2-(n-butanesulphonylamino)-2-carboxy-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine- ~ -hydrochloride (44) 4-[4-[[4-E2-carboxy-2-(hexanoylamino)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (45) 4-[4-[[trans-4-(carboxymethoxy)-cyclohexyl]- ~-aminocarbonyl]-phenyl]-piperidine-hydrochloride -(46) 4-[4-[[4-(2-carboxyethyl)-phenyl~-aminocarbonyl]-piperidino]-pyridine-hydrochloride -(47) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-piperidino]-pyridine-hydrochloride (48) 4-[4-[[4-[2-(n-butanesulphonylamino)-2-carboxy- ~
ethyl]-phenyl]-aminocarbonyl]-piperidino]-pyridine- ~ : :
hydrochloride (49) 4-[4-[[4-[2-carboxy-2-(n-hexanoylamino)-ethyl]- :~
phenyl]-aminocarbonyl]-piperidino]-pyridine-hydrochloride : ' :,- ~' : ~

-' 211103 (50) 4-[4-~[trans-4-[2-(n-butanesulphonylamino)-2-carboxyethyl]-cyclohexyl]-aminocarbonyl]-piperidino]-pyridine-hydrochloride (51) 4-[4-[[trans-4-[2-carboxy-2-(n-hexanoylamino)-ethyl]-cyclohexyl]-aminocarbonyl]-piperidino]-pyridine-hydrochloride (52) 4-[3-[[4-[2-(benzylsulphonylamino)-2-carboxy-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (53) 4-[3-[[4-[2-carboxy-2-(n-hexanoylamino)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (54) 4-[4-[[4-[2-(benzylsulphonylamino)-2-carboxy-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (55) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-3-fluoro-phenyl]-piperidine-hydrochloride (56) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-3-ethoxy-phenyl]-piperidine-hydrochloride The same procedure is used as in (2) (57~ 1-[2-bromo-4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperazine- -hydrochloride ---~
(58) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-3-chloro-phenyl]-piperidine-hydrochloride ~,- -(59) 4-[4-[[2-bromo-4-(2-carboxyethyl)-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride 2111~3~
(60) 4-[4-[[4-(2-carboxyethyl)-2-methoxy-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (61) 1-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-2-methylthio-phenyl]-piperazine-hydrochloride (62) 1-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-2-methylsulphonyl-phenyl]-piperazine-hydrochloride (63) 4-[4-[[4-(2-carboxyethyl)-2-methyl-phenyl]- :
aminocarbonyl]-phenyl]-piperidine-hydrochloride (64) 4-[4-[[4-(2-carboxyethyl)-phenyl]-sulphonylamino]-phenyl]-piperidine-hydrochloride (65) 4-[4-[[4-(2-carboxyethenyl)-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (66) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-l-methyl-piperidine-hydrochloride Melting point: >300C -Mass spectrum: M~ = 372 : -(67) 4-[1-[[trans-4-~2-carboxyethyl)-cyclohexyl]-aminocarbonyl3-piperidino]-piperidine-hydrochloride ~, ~
(68) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-piperidino]-piperidine-dihydrochloride .- .:.
Yield: 0.77 g (79.5% of theory), :~-~
Melting point: 297-300C (decomp.) (69) 1-[4-[[4-(carboxymethoxy)-phenyl]-carbonylamino]-: :~
phenyl]-piperazine-hydrochloride ~;

- 78 - 2111~35 (70) 4-[4-[[4-(2-carboxyethenyl)-phenyl]-carbonylamino~-phenyl]-piperidine-hydrochloride (71) 4-[4-[[4-(2-carboxyethyl)-phenyl]-carbonylamino]-phenyl]-piperidine-hydrochloride (72) 4-[4-[~trans-4-(carboxy)-cyclohexyl]-methyl-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: 109-110C
(73) 4-[2-[4-(2-carboxyethyl)-phenyl]-1-oxo-2,3-dihydro-isoindol-6-yl]-piperidine-hydrochloride --Melting point: 291-293C
Rf value: 0.52 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) ~
(74) 2-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]- ~ ;
aminocarbonyl]-phenyl]-ethylamine-hydrochlor~de -Melting point: >250C ~ :
Rf value: 0.65 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) (75) 4-[4-[[trans-4-(carboxymethoxy)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: >250C
Rf value: 0.65 (Reversed Phase Plate RP8; methanol/5% ~ ~.
sodium chloride solution = 6:4) ~-(76) 4-[4-[[trans-4-carboxy-cyclohexyl]-aminocarbonyamino]-phenyl]-piperidine-hydrochloride Melting point: >200~C
Rf value: 0.70 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) :~
(77) 4-[4-[[4-(2-carboxyethyl)-phenyl]-aminomethyl]-phenyl]-piperidine-hydrochloride : .

21110.~
(78) 4-[4-[[4-(2-carboxyethyl)-piperidinyl]-carbonyl]-phenyl]-piperidine-hydrochloride Melting point: 207-208C (decomp.) (79) 4-[2-[trans-4-(2-carboxyethyl)-cyclohexyl]-1-oxo-2,3-dihydro-isoindol-6-yl]-piperidine-hydrochloride `
Rf value: 0.50 (Reversed Phase Plate RP8; methanol/5 sodium chloride solution = 6:4) (80) 4-[2-[trans-4-(2-carboxyethyl)-cyclohexyl]-1-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride Rf value: 0.50 (Reversed Phase Plate RP8; methanol/5% : -:
sodium chloride solution = 6:4) Melting point: >300OC
(81) 4-[2-[4-(2-carboxyethyl)-phenyl]-1-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride ~-:
Melting point: 303-306C ~- .
(82) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-l-aza-bicyclo[2.2.1]heptane-hydrochloride -`~
(83) 4-[4-[[trans-4-(carboxy)-cyclohexyl]-methylaminocarbonyl]-piperidine-hydrochloride Rf value: 0.56 (Reversed Phase Plate RP8i methanol/5%
sodium chloride solution = 6:4) ~ `:
': "' '' ~
Exam~le 4 4-[4-[[4-[2-(Methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-1-methyl-piperidine-hydrochloride 0.8 g of 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride are dissolved in 35 ml of methanol, mixed with 0.42 g of paraformaldehyde and 0.45 g of sodium cyanoborohydride ~, ^` 2111~35 and stirred for 3 hours at ambient temperature, whil~t the pH is maintained between 3 and 6 by the addition o~
lN hydrochloric acid. Then a further 0.5 g of paraformaldehyde and 0.5 g of sodium cyanoborohydride are added and the mixture is stirred for 16 hours at ambient temperature whilst maintaining the above-mentioned acidity of the solution. It is then made alkaline with lON sodium hydroxide solution, extracted with ethyl acetate, the organic phase is evaporated down -and purified by chromatography on silica gel (eluant:
methylene chloride/methanol = 9:1).
Yiald: 0.58 g (76% of theory), Melting point: 161-164C
Rf value: 0.17 (silica gel; methylene chloride/methanol =
9 : 1 ) , . :
Mass spectrum: M~ = 380 ~ -The following compounds are obtained analogously: ~ -(1) 1-isopropyl-4-[4-[[trans-4-[2-(methoxycarbonyl)- --ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine -' :' ' (2) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]~
cyclohexyl]-aminocarbonyl]-phenyl~-1-methyl-piperidine Melting point: 202-204C -~, (3) 4-[2-[trans-4-(2-carboxy-ethyl)cyclohexyl]-1-oxo-2,3-dihydro-isoindol-5-yl]-1-methyl-piperidine-hydrochloride Melting point: 301-303C
Prepared from 4-[2-(trans-4-(2-carboxy-ethyl)-cyclohexyl]-l-oxo-2,3-dihydro-isoindol-5-yl]-piperidine with paraformaldehyde and formic acid.

(4) 3-[4-[[trans-4-(2-carboxyethyl)cyclohexyl]- ~-aminocarbonyl]-phenyl]-l-methyl-pyrrolidine-hydrochloride ::

`` -` 2111~3~

Melting point: 246-250C
Prepared from 3-[4-[[trans-4-(2-carboxy-ethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-pyrrolidine-hydrochloride with paraformaldehyde and formic acid.

Example 5 4-[3-[[trans-4-[2-(Methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride 1.7 g of 1-benzyl-4-[3-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-3,4-dehydro-piperidine are dissolved in 40 ml of methanol, mixed -with 2 ml of methanolic hydrochloric acid and 0.5 g of -~
palladium hydroxide on charcoal and hydrogenated with hydrogen under 5 bars of pressure at 50C. Then the ;~
catalyst is filtered off and the filtrate is evaporated ~ - -down ln vacuo.
Yield: 1.30 g (87% of theory), Rf value: 0.25 (Reversed Phase Plate RP8; methanol/5% -sodium chloride solution = 6:4) Mass spectrum: M' = 372 The following compounds are obtained analogously:

(1) 4-[3-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine The work is done without the addition of hydrochloric acid, using 10% palladium charcoal.
Rf value: 0.27 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) (2) 4-[3-[[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl3-j piperidine-hydrochloride The same procedure is used as in (1) but at 60~C.
R~ value: 0.28 (Reversed Phase Plate RP8; methanol/5%

2ill~3~
- ~2 -sodium chloride solution = 6:4) Mass spectrum: (M+H)+ = 502 (3) 1-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperazine-hydrochloride Prepared by debenzylation of 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-l-benzyl-piperazine in the presence of 10%
palladium charcoal.
Melting point: 190-192C

(4) 4-[2-[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-1-oxo- ;~
2,3-dihydro-isoindol-6-yl]-piperidine-hydrochloride - ~:~

(5) 4-[2-[trans-4-[2-(methoxycarbonyl)-ethyl]- -d -cyclohexyl]-l-oxo-2,3-dihydro-isoindol-6-yl]-piperidine- - :-hydrochloride :
Melting point: 175-178C
Prepared from l-benzyl-4-~2-[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-l-oxo-2,3-dihydro-I isoindol-6~yl]-3,4-dehydro-piperidine and palladium hydroxide on charcoal as catalyst.

(6) 4-[2-[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-1-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride ~-Melting point: 260-262C

(7) 4-[2-[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-1-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride Melting point: 232-235C

.
..' . ~
' ~ :

2illO3~

Example 6 l-Benzyl-4-[3-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-3,4-dehydro-piperidine -2 g of 1-Benzyl-4-(3-carboxyphenyl)-3,4-dehydro- -piperidine-hydrochloride are refluxed for 45 minutes in 3.5 ml of thionylchloride and then evaporated to dryness in vacuo. The acid chloride thus obtained is added in batches to a solution (cooled to 0C) of 1.3 g of methyl 3-(trans-4-amino-cyclohexyl)-propionate-hydrochloride and 3.3 ml of N-ethyl-diisopropylamine in 50 ml of methylene chloride. After 2 hours, 300 ml of methylene chloride and 15 ml of methanol are added, the mixture is washed successively with water, O.lN sodium hydroxide solution, water, O.lN hydrochloric acid and water and the organic phase is evaporated down. The product is purified by column chromatography over silica gel (eluant: methylene chloride/methanol = 9:1) Yield: 1.8 g (64% of theory), Rf value: 0.42 (silica gel; methylene chloride/methanol =
9 : 1 ) The following compounds are obtained analogously:

(1) 1-benzyl-4-[3-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-3,4-dehydro-piperidine Melting point: 194-196C
Rf value: 0.66 (silica gel; methylene chloride/methanol =
9 : 1 ) (2) 1-benzyl-4-[3-[[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-3,4-dehydro-piperidine-hydrochloride Rf value: 0.25 (silica gel; methylene chloride/methanol =
20:1) ',:
-` --" 21~1035 Example 7 4-[4-[[4-(2-Carboxyethyl)-phenyl]-aminomethyl]-phenyl]-piperidine-hydrochloride 0.7 g of 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-aminomethyl]-phenyl]-l-trifluoroacetyl-piperidine, 10 ml of glacial acetic acid and l ml of conc. hydrochloric acid are stirred for 4 hours at 80C and for 16 hours at ambient temperature. The mixture is evaporated to dryness ln vacuo, evaporated down several times with toluene and the residue is stirred with 50 ml of acetone.
Yield: 0.39 g (66% of theory), Rf value: 0.76 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 9:1) Mass spectrum: M+ = 338 The following compounds are obtained analogously:

(1) 4-[2-[trans-4-(2-carboxyethyl)-cyclohexyl]-l-oxo-2,3-dihydro-isoindol-6-yl]-piperidine-hydrochloride (2) 4-[2-[4-[2-(n-butanesulphonylamino)-2-carboxy-ethyl]-phenyl]-l-oxo-2,3-dihydro-isoindol-6-yl]-piperidine-hydrochloride (3) 4-[4-[~trans-4-(2-carboxyethyl)-cyclohexyl]-aminomethyl]-phenyl]-piperidine-dihydrochloride -~
Melting point: 308-311C (decomp.) (4) 4-[4-[N-[trans-4-(2-carboxyethyl)-cyclohexyl]-N-methylaminomethyl]-phenyl]-piperidine-dihydrochloride (5) 4-[4-[N-[trans-4-(2-carboxyethyl)-cyclohexyl]-N-(2- - -phenyl-ethyl)-aminomethyl]-phenyl]-piperidine-dihydrochloride ',' '~ :' :, ,:

_ ~5 _ 211103~
(6) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl~-aminosulphonyl]-phenyl]-piperidine-hydrochloride (7) 4-[4-[2-[4-(2-carboxyethyl)-phenyl]-ethenyl]-phenyl]-piperidine-hydrochloride (8) 4-[2-[trans-4-(2-carboxyethyl)-cyclohexyl]-l-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride (9) 4-[2-~4-(2-carboxyethyl)-phenyl]-1-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride (10) 4-[2-[4-[2-(n-butanesulphonylamino)-2-carboxy-ethyl]-phenyl]-1-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride (11) 4-[2-[trans-4-(2-carboxyethyl)-cyclohexyl]-1-oxo-~,4-dihydro-isoquinolin-7-yl]-piperidine-hydrochloride (12) 4-[2-[4-(2-carboxyethyl)-phenyl]-1-oxo-3,4-dihydro-isoquinolin-7-yl]-piperidine-hydrochloride (13) 4-[2-[4-(2-carboxyethyl)-phenyl]-1-oxo-2,3-dihydro- :
isoindol-6-yl]-piperidine-hydrochloride ~
-.
(14) 4-[4-[2-[4-(2-carboxyethyl)-phenyl]-ethyl3-phenyl]-piperidine-hydrochloride (15) 4-[4-[[4-(2-carboxyethyl)-phenyl]-methylamino]-phenyl]-piperidine-hydrochloride (16) 4-[4-[(trans-4-carboxy-cyclohexyl)-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: above 310C
Rf value: 0.13 (silica gel; methylene chloride/
methanol/conc. ammonia = 4:1:0.25) - ` 2 ~ 3 ~

(17) 4-[4-[[4-(carboxymethyloxy)-phenyl]-carbonylamino]-phenyl]-piperidine-hydrochloride Prepared from 4-[4-[[4-(tert.butyloxycarbonyl-methyloxy)-phenyl]-carbonylamino]-phenyl]-1-trifluoroacetyl-piperidine Rf value: 0.10 (silica gel; methylene chloride/
methanol = 9:1) Mass spectrum: (M+H)+ = 355 Exam~le 8 4-[4-[[4-~2-(Methoxycarbonyl)-ethyl]-phenyl]-aminomethyl]-phenyl]-1-trifluoroacetyl-piperidine 8.6 g of 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-iminomethyl]-phenyl]-1-trifluoroacetyl-piperidine are dissolved in 100 ml of ethyl acetate and hydrogenated initially for 1.5 hours in the presence of 0.5 g of platinum dioxide at ambient temperature using a hydrogen pressure of 5 bar. A further 0.5 g of platinum dioxide ~ -are added and the temperature is increased to 50C.
After 3 hours a further 0.5 g of platinum dioxide are added and hydrogenation is continued for a further 4 hours. After the catalyst has been filtered off the solvent is removed and the residue is purified by column chromatography over silica gel (eluant~
cyclohexane/ethyl acetate = 3:1) Yield: 3.6 g (42% of theory), ~ -Rf value: 0.50 (silica gel; cyclohexane/ethyl acetate =
2:1) --~

- ~.

- 87 - 211103~
Example 9 4-[4-[[trans-4-[2-(Isopropyloxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride 0.15 g of 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride are suspended in a mixture of 100 ml of isopropanol and 50 ml of ethereal hydrochloric acid and stirred for 16 hours at ambient temperature. The product is obtained by evaporating the solution down in vacuo.
Yield: 0.135 g (81% of theory), Melting point: 255-260C
Rf value: 0.31 (silica gel; methylene chloride/methanol/
conc. ammonia = 4:1:0.25) Mass spectrum: M' = 400 ~he following compounds are obtained analogously: ;

(1) 4-[4-[[trans-4-[2-(sec.butyloxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride (2) 4-[4-[[trans-4-[2-(cyclohexyloxycarbonyl~-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine- -hydrochloride Melting point: 238-240C

(3) 4-[4-[[trans-4-[2-(isobutyloxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: 238-240C

(4) 4-[4-[[trans-4-[2-[(2-phenylethyl)-oxycarbonyl]-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride 2111~
- ~8 -(5) 4-[2-[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-1-oxo-2,3-dihydro-isoindol-6-yl]-piperidine-hydrochloride (6) 4-~2-[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-l-oxo-2,3-dihydro-isoindol-6-yl]-piperidine-hydrochloride (7) 4-[2-[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-l-oxo-2,3-dihydro-isoindol-6-yl]-piperidine-hydrochloride (8) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminomethyl]-phenyl]-piperidine-di-trifluoroacetate :- -Melting point: 77-79C (decomp.) ~:

(9) 4-[4-[N-[trans-4-[2-(methoxycarbonyl)-ethyl]- -~
cyclohexyl]-N-methyl-aminomethyl]-phenyl]-piperidine-dihydrochloride -~ .

(10) 4-[4-[N-[trans-4-[2-(methoxycarbonyl)-ethyl]- -cyclohexyl]-N-(2-phenylethyl)-aminomethyl]-phenyl]-piperidine-dihydrochloride :~

(11) 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminosulphonyl]-phenyl]-piperidine-hydrochloride :~

(12) 4-[4-[2-[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-ethenyl]-phenyl]-piperidine-hydrochloride ::'-(13) 4-[2-[trans-4-[2-(methoxycarbonyl)-e~hyl]- :~-cyclohexyl]-l-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride (14) 4-[2-[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-1-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride - 89 - 211103~
(15) 4-[2-[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-l-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride (16) 4-[2-[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-l-oxo-3,4-dihydro-isoquinolin-7-yl]-piperidine-hydrochloride (17) 4-[2-[4-[~-(methoxycarbonyl)-ethyl]-phenyl]-1-oxo-3,4-dihydro-isoquinolin-7-yl]-piperidine-hydrochloride (18) 4-[4-[2-[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-ethyl]-phenyl]-piperidine-hydrochloride (19) 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl]-methylamino]-phenyl]-piperidine-hydrochloride (20) 4-[4-[[4-[2-(methoxycarbonyl)-ethyl]-phenyl~- -aminomethyl]-phenyl]-piperidine-hydrochloride (21) 4-[4-[[trans-4-(isopropylcarbonyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: 270C (sintering from 250~C) Rf value: 0.38 (silica gel; methylene chloride/
methanol/conc. ammonia = 4:1:0.25) (22) 4-[4-[[trans-4-[2-(ethoxycarbonyl)-ethyl~-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride Melting point: 246-248~C

(23) 4-[4-[[trans-4-(ethoxycarbonyl-meth,vloxy)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine-hydrochloride , Rf value: 0.60 (Reversed Phase Plate RP8; methanol/5%
; sodium chloride soluti.on = 6:4) (24) 4-[4-[[4-(methoxycarbonyl~methyloxy)-phenyl]-carbonylamino]-phenyl]-piperidine (25) 4-[2-[trans-4-t2-(ethoxycarbonyl) ethyl]-cyclohexyl]-l-oxo-2,3-dihydro-isoindol-5-yl]-piperidine-hydrochloride Melting point: 260-264C

Example 10 l-(Methoxycarbonyl)-4-[4-[[trans-4-[2-(methoxycarbonyl~- :
ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine ~-Prepared from 4-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine and -methylchloroformate in methylene chloride in the --presence of 0.2N sodium hydroxide solution.

The following compound is obtained analogously~

(1) 1-(acetoxy-methoxycarbonyl)-4-[4-[[trans-4-[2- , (methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]- --phenyl]-piperidine -Exam~le 11 -~

2-[4-[[trans-4-[2-(Methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-ethylamine-hydrochloride A solution of 1.6 g (4.87 mMol) of 2-[4-[[trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-acetonitrile in 400 ml of methanol is acidified with methanolic hydrochloric acid and then hydrogenated in the presence of 0.5 g of palladium on charcoal (10~) at ambient temperature under a pressure of 3 bar until the uptake of hydrogen has ceased. Then the catalyst is ,, .
-~,, ::

211103~

removed by suction filtering and the filtrate is evaporated to dryness under reduced pressure. The residue is triturated with a 1:1 mixture of tert.butyl-methylether and ethyl acetate, heated, cooled down to ambient temperature once more and suction filtered.
After decoction with acetone and suction filtering again, 1.2 g = 66.7~ of a yellowish crystalline compound are obtained.
Melting point: >250C -Rf value: 0.45 (silica gel; dichloromethane/methanol =

Example 12 4-[1-[[trans-4-[2-(Methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-piperidino]-piperidine To an equimolar solution of trans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexylamine and p-nitrophenyl chloroformate in dry tetrahydrofuran, a solution of 2 equivalents of triethylamine in tetrahydrofuran is added dropwise with stirring at O-C
and the resulting mixture is stirred for another 2.5 hours at 0C. Then, as stirring continues, one equivalent of 4,4'-bipiperidyl is added dropwise, the mixture is then stirred for 16 hours at ambient temperature and for another 4 hours at 50C. Then it is evaporated to dryness under reduced pressure, the residue is taken up in ethyl acetate and this ethyl !
acetate solution is washed with lN sodium hydroxide solution and then with water, dried over sodium sulphate and evaporated to dryness under reduced pressure. The crude product remaining is chromatographed over silica gel, using ethyl acetate as eluant.

-:`` 2111035 Example 13 4-[4-[[4-(2-Carboxyethyl)-piperidino]-methyl]-phenyl~-piperidine dihydrochloride 1.3 g (0.0029 Mol) of l-tert.butyloxycarbonyl-4-[4-[[2-(methoxycarbonylethyl)-piperidino]-methyl]-phenyl]-piperidine are stirred for 15 minutes at ambient -temperature in 80 ml of semiconcentrated hydrochloric acid. Then the mixture is evaporated to dryness vacuo and the residue remaining is digested three times with acetone and the resinous residue remaining is dried in vacuo. -Yield: 0.82 g (77.1% of theory), , Rf value: 0.54 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) H-NMR spectrum (200 MHz, DMS0-d6); signals at ppm: -1.3-1.7 (m, 5H), 1.7-2.0 (m, 6H); 2.15-2.3 (t, 2H); 2.7 3.1 (m, 4+1H); 3.2-3.55 (m, 4H); 4.15-4.2 (d, 2H); 7.3 (d, 2H); 7.6 (d, 2H); 9.1 (s, 2H); 10.7 (s, lH~; 12.05 (s, lH) : ~
The following compounds are prepared analogously:

(1) 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]- ~-~
aminomethyl]-phenyl]-piperidine-dihydrochloride Melting point: 308-311C (decomp.) Prepared from 1-tert.butyloxycarbonyl-4-[4-[[trans-4-(2-methoxycarbonyl-ethyl)-cyclohexyl]-aminomethyl]-phenyl]-piperidine and semiconcentrated hydrochloric acid.

(2) 3-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl~-pyrrolidine-hydrochloride (3) 3-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-3-methyl-pyrrolidine-hydrochloride `:` 2111~35 (4) 4-[2-[trans-4-(2-carboxyethyl)-cyclohexyl]-1-oxo-2,3-dihydro-isoindol-6-yl~-pyridine Rf value: 0.39 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6:4) (5) 1-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminomethyl]-phenyl]-piperazine-dihydrochloride Melting point: 245-248C (decomp.) Prepared from 1-tert.butyloxycarbonyl-4-[4-[[trans-4-(2-methoxycarbonyl-ethyl~-cyclohexyl]-aminomethyl]-phenyl]-piperazine and semiconcentrated hydrochloric acid.

(6) 3-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-amino-carbonyl]-phenyl]-pyrrolidine-hydrochloride Melting point: > 250C
Rf value: 0.55 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6/4) Prepared from l-tert.butyloxycarboxyl-3-[4-[[trans-4-t2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-pyrrolidine and half-concentrated hydrochloric acid.

(7) 3-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-amino-carbonyl]-phenyl]-3-methyl-pyrrolidine-hydrochloride Melting point: >250C
Rf value: 0.5 (Reversed Phase Plate RP8; methanol/5%
sodium chloride solution = 6/4) Prepared from 1-tert.butyloxycarbonyl-3-[4-[[trans-4-[2-(methoxycarbonylethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-3-methyl-pyrrolidine and semi-concentrated hydrochloric acid. -~-2111~3~

Example 14 Dry ampoule containing 2.5 mg of active substance per 1 ml , Composition:
: : -Actîve substance 2.5 mg - -Mannitol 50.0 mg Water for injections ad1.0 ml -Preparation~

The active substance and mannitol are dissolved in water. After transferring the solution to the ampoule, it is freeze-dried.

When required for use, the solution is made up with water for injections.

Example 15 -Dry ampoule containing 35 mg of active substance per 2 ml ~ -Composition:

Active substance 35.0 mg Mannitol lO0.0 mg Water for injections ad2.0 ml Preparation: -¦ The active substance and mannitol are dissolved in -~
, water. After transferring the solution to the ampoule, 211103~

it is freez~-dried.

When required for use, the solution is made up with water for injections.

ExamPle 16 Tablet containing 50 mg of active substance -Composition:

(1) Active substance 50.0 mg (2) Lactose 9~.0 mg (3) Corn starch 50.0 mg (4) Polyvinylpyrrolidone 15.0 mg (5) Magnesium stearate 2.0 mq 215.0 mg Preparation:

Components (1), (2) and (3) are mixed together and granulated with an aqueous solution of component (4).
Component (5) is added to the dried granules. From this mixture, compressed tablets are produced, biplanar, facetted on both sides and notched on one side.
Diameter of tablets: 9 mm.

~xample 17 Tablet containing 350 mg of active substance . ~ .

Composition:

~.

211103~
- ~6 -(1) Active substance 350.0 mg (2) Lactose 136.0 my (3) Corn starch 80.0 mg (4) Polyvinylpyrrolidone30.0 mg (5) Magnesium stearate 4.0 mg 600.0 mg Preparation:

Components (l), (2) and (3) are mixed together and granulated with an aqueous solution of component (4).
Component (S) is added to the dried granules. From this mixture, compressed tablets are produced, biplanar, ~acetted on both sides and notched on one side.
Diameter of tablets: 12 mm.

Example 18 Capsules containing 50 mg of active substance .:
Composition:

(l) Active substance 50.0 mg (2) Dried corn starch 58.0 mg (3) Powdered lactose 50.0 mg (4) Magnesium stearate 2.0 mq 160.0 mg Preparation:

Component (1) is triturated with component (3). This triturate is added to the mixture of components (2) and (4), with thorough mixing. ;

This powdered mixture is packed into size 3 hard gelatin ~ -oblong capsules in a capsule filling machine. ;~

--~` 2 ~ 3 ~

Example 19 Capsules containing 350 mg of active substance , Composition:

tl) Active substance 350.0 mg (2) Dried corn starch 46.0 mg (3) Powdered lactose 30.0 mg (4) Magnesium stearate 4.0 ma 430.0 mg Preparation: : , .
Component (1) is triturated with component (3). This ~
triturate is added to the mixture of components (2) and -.-t4), with thorough mixing. ~ -This powdered mixture is packed into size O hard gelatin oblong capsules in a capsule filling machine.
,.

.~
: ~ .

Claims (11)

1. Compounds of formula I

A - B - C - D - E - COORa (I) (wherein:

Ra denotes a hydrogen atom or a C1-5-alkyl, C3-5-alkenyl, phenyl(C1-3-alkyl), C5-7-cycloalkyl or R1-CO-O-(R2CH)-group;

R1 denotes a C1-5-alkyl, C5-7-cycloalkyl, phenyl(C1-3-alkyl), C1-5-alkoxy, C5-7-cycloalkoxy or phenyl group;

R2 denotes a hydrogen atom or a C1-4-alkyl, C5-7-cycloalkyl or phenyl group;

A denotes a C1-5-aminoalkyl group linked to group B via a carbon atom of A, or A denotes a 5-, 6- or 7-membered azacycloalkyl group linked to group B via a carbon atom of the azacycloalkyl group, or A denotes a quinuclidinyl or pyridyl group, wherein the nitrogen in the above-mentioned aminoalkyl or azacycloalkyl groups is optionally substituted by a group Rb, wherein the carbon atoms of the azacycloalkyl group are optionally substituted by 1 to 3 C1-3-alkyl groups or by an aminocarbonyl, cyano, R3O- or R3O-CO- group, wherein, in a 6- or 7-membered azacycloalkyl group A a >CH- unit in the 4-position relative to the ring nitrogen is optionally replaced by a nitrogen atom, wherein in a 5-, 6- or 7-membered azacycloalkyl group A
a -CH2-CH< unit may be replaced by a -CH=C< unit and wherein in a piperazinyl or homopiperazinyl group A a ring carbon adjacent to the nitrogen atom in the 4-position is optionally oxo-substituted;

Rb denotes a C1-3-alkyl, phenyl(C1-3-alkyl), C2-4-alkanoyl, trifluoroacetyl, (C1-5-alkoxy)carbonyl, phenyl (C1-3-alkoxy)carbonyl, (C3-5-alkenyl)oxycarbonyl or an R1-CO-O-(R2CH)-O-CO- group;

R3 denotes a hydrogen atom, or a C1-3-alkyl or phenyl-(C1-3)-alkyl group, B denotes a phenylene group optionally mono- or disubstituted by fluorine, chlorine or bromine atoms, by trifluoromethyl groups, or by C1-3-alkyl, C1-3-alkoxy, C1-3-alkylsulphenyl, C1-3-alkylsulphinyl or C1-3-alkylsulphonyl groups, wherein the substituents may be identical or different and wherein, additionally, 1 or 2 unsubstituted methine groups may each be replaced by an N-atom, or B denotes a piperidinylene group, C denotes a carbonyl, -CH2CH2-, -CH=CH-, -CH2-, -CH20-, -OCH2-,-CONR4-, -CONR4-CH2-, -NR4CO-, -NR4CO-NR4, -CH2NR4-,-NR4CH2-, -SO2NR4-, -SO2NR4-CH2- or -NR4SO2- group;
R4 denotes a hydrogen atom or a C1-3-alkyl or phenyl(C1-3-alkyl) group, or if C denotes a -CONR4- group bound to group B via the carbonyl group, R4 may also denote a methylene or 1,2-ethylene group bound to the carbon atom of group B in the ortho-position relative to the point of linkage of the -CONR4- group;

D denotes a phenylene group optionally mono- or disubstituted by fluorine, chlorine or bromine atoms, by trifluoromethyl groups, by C1-3-alkyl, C1-3-alkoxy, C1-3-alkylsulphenyl, C1-3-alkylsulphinyl or C1-3-alkylsulphonyl groups, wherein the substituents may be identical or different, and wherein additionally 1 or 2 unsubstituted methine groups may each be replaced by an N-atom, or D
denotes a C5-7-cycloalkylene group wherein one or two >CH- units may be replaced by an N-atom and additionally in an aza- or diazacyclohexylene ring thus formed, a ring carbon adjacent to a ring nitrogen is optionally oxo-substituted;
E denotes a bond, a C1-3-alkyleneoxy group bound to group D through the oxygen atom, a straight-chain C1-5-alkylene group optionally substituted by 1 or 2 C1-8-alkyl groups, or by a hydroxy, C1-8-alkoxy, R5NH-, R5N(C1-8alkyl) or R5N(phenylC1-3-alkyl) group, or E denotes a C2-5-alkenylene group optionally substituted by one or two C1-8-alkyl groups;
R5 denotes a hydrogen atom or a C1-8-alkyl, ( C1-4-alkoxy)carbonyl, or phenyl(C1-3-alkoxy)carbonyl group or a carbonyl or sulphonyl group substituted by a C1-8-alkyl group or by a C3-7-cycloalkyl, phenylC1-3-alkyl or phenyl group, wherein each phenyl moiety in R5 is optionally mono- or disubstituted by fluorine, chlorine or bromine atoms, by trifluoromethyl groups, or by C1-3-alkyl, C1-3-alkoxy, C1-3-alkylsulphenyl, C1-3-alkylsulphinyl or C1-3-alkylsulphonyl groups and the substituents may be identical or different;
wherein (i) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an Rb-NH-CH2- group wherein Rb is a benzyloxycarbonyl group, then RaOOC-E-D-C- does not denote a 3-carboxy-phenylaminocarbonyl group, (ii) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an Rb-NH-CH2- group wherein Rb denotes a hydrogen atom or an acetyl group, then RaOOC-E-D-C- does not represent a phenylcarbonyl group substituted in the 4-position by a carboxymethyl, methoxycarbonylmethyl, 2-carboxy-ethyl, 2-methoxycarbonyl-ethyl or 2-ethoxycarbonylethyl group, (iii) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an NH2-CH2-CH2- group, then RaOOC-E-D-C- does not denote a 4-ethoxycarbonyl-phenylcarbonyl group, (iv) if the A-B- moiety denotes a 4-aminomethyl-phenyl-, 3-aminomethyl-phenyl-, 4-aminomethyl-3-methoxy-phenyl-or 3-aminomethyl-4-methoxyphenyl group, then RaOOC-E-D-C-does not denote a 4-ethoxycarbonylmethoxy-2,3-dichlorophenylcarbonyl group, (v) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an NH2-CH2- or (CH3)3CO-CO-NH-CH2- group, then RaOOC-E-D-C- does not denote a 4-carboxyphenylmethoxy group, (vi) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an NH2-CH2- group, then RaOOC-E-D-C- does not denote a 4-carboxy-phenylaminosulphonyl group, (vii) if the A-B- moiety denotes a 4-(2-pyridyl)-phenyl-or 4-(3-pyridyl)-phenyl group, then RaOOC-E-D-C- does not denote a 4-carboxy-phenylcarbonylamino, 4-benzyloxycarbonyl-phenylcarbonylamino- or 2-(4-carboxy-phenyl)-ethyl group, and (viii) if the A-B- moiety denotes a 3-(4-pyridyl)-phenyl group, then RaOOC-E-D-C- does not denote a 2-(carboxymethyl)-phenylcarbonylamino group) and the isomers and salts thereof.
2. Compounds of formula I according to claim 1 wherein RA denotes a hydrogen atom or a C1-5-alkyl, phenyl(C1-3-alkyl) or C5-7-cycloalkyl group;

A denotes a C2-5-aminoalkyl group linked to group B via a carbon atom of A, or a piperidinyl group linked to group B via a carbon atom of the piperidinyl group, or A
denotes a quinuclidinyl or pyridyl group, wherein the nitrogen of the above-mentioned aminoalkyl or piperidinyl groups is optionally substituted by a group Rb, wherein the carbon atoms of the piperidinyl group are optionally substituted by methyl, cyano, carboxy, methoxycarbonyl or aminocarbonyl groups, and wherein in a piperidinyl A group a >CH- unit in the 4-position may be replaced by a nitrogen atom or a -CH2-CH< unit may be replaced by a -CH=C< unit;

Rb denotes a C1-3-alkyl, benzyl, (C1-5-alkoxy)carbonyl, benzyloxycarbonyl or CH3-CO-O-(CH2)-O-CO- group;

B denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a C1-2-alkyl, C1-2-alkoxy, C1-2-alkylsulphenyl, C1-2-alkylsulphinyl or C1-2-alkylsulphonyl group, or B denotes a pyridinylene or piperidinylene group;

C denotes a -CO-, -CH2CH2-, -CH=CH-, -CH2-, -CH20-, -OCHz-, -CONR4 -, -NR4CO-, -NR4CO -NR4-, -CH2NR4-, -NR4CH2-, -SO2NR4- or -NR4SO2- group;

R4 denotes a hydrogen atom or a C1-2-alkyl or phenyl(C1-2-alkyl) group or, if C denotes a -CONR4 group bound to group B via the carbonyl group, R4 may also denote a methylene or 1,2-ethylene group bound to the carbon atom of group B in the ortho- position relative to the point of linkage of the -CONR4 group;

D denotes a phenylene group optionally substituted by a chlorine or bromine atom, or by a C1-2-alkyl or C1-2-alkoxy group, or D denotes a cyclohexylene group in which one or two >CH- units may be replaced by N-atoms, and additionally, in a piperidinylene or piperazinylene D
group a ring carbon adjacent to a ring nitrogen is optionally oxo-substituted;

E denotes a bond, a methyleneoxy group bound to group D
through the oxygen atom, a 1-2-ethenylene group or a straight-chain C1-5-alkylene group which may be substituted by a C1-7-alkyl group or by an R5NH- group;
and R5 denotes a hydrogen atom or a C1-7-alkylcarbonyl, benzylcarbonyl, C1-5-alkylsulphonyl or benzylsulphonyl group;

wherein (iii) if the A-B- moiety denotes a phenyl group substituted in the 4-position by an NH2-CH2-CH2- group, then RaOOC-E-D-C does not denote a 4-ethoxycarbonyl-phenylcarbonyl group, and (vii) if the A-B- moiety denotes a 4-(2-pyridyl)-phenyl-or 4-(3-pyridyl)-phenyl group, then RaOOC-E-D-C- does not denote a 4-carboxy-phenylcarbonylamino, 4-benzyloxycarbonyl-phenylcarbonylamino- or 2-(4-carboxy-phenyl)-ethyl group, and (viii) if the A-B- moiety represents a 3-(4-pyridyl)-phenyl group, then RaOOC-E-D-C- does not denote a 2-(carboxymethyl)-phenylcarbonylamino group;

and the tautomers, stereoisomers and salts thereof.
3. Compounds of formula I according to claim 1, wherein Ra denotes a hydrogen atom or a C1-4-alkyl, 2-phenylethyl or cyclohexyl group;

A denotes a C3-5-aminoalkyl group linked to group B via a carbon atom of A, or a piperidinyl group linked to group B via a carbon atom of the piperidinyl group or A
denotes a quinuclidinyl or 4-pyridyl group, wherein the nitrogen atom in the above-mentioned piperidinyl group is optionally substituted by a group Rb, wherein the carbon atoms of the piperidinyl group are optionally substituted by methyl, cyano, carboxy, methoxycarbonyl or aminocarbonyl groups, and wherein in a piperidinyl A group a >CH- unit in the
4-position may be replaced by a nitrogen atom or a -CH2-CH< unit may be replaced by a -CH=C< unit;

Rb denotes a C1-3-alkyl, benzyl, (C1-4-alkoxy)carbonyl or CH3-CO-O-(CH2)-O-CO- group;

B denotes an optionally methyl- or methoxy- substituted phenylene group or a 2,5-pyridinylene or 1,4-piperidinylene group;

C denotes a -CO-, -CH2CH2-, -CH=CH-, -CH2-, -CH2O-, -OCH2-, -CONR4-, -NR4CO-, -NR4CO-NR4- or -CH2NR4- group or an -SO2NR4- group wherein the SO2 moiety is linked to group B;

R4 denotes a hydrogen atom or a methyl or 2-phenylethyl group or, if C denotes a -CONR4- group bound to group B
via the carbonyl group, R4 may also denote a methylene or 1,2-ethylene group bound to the carbon atom of group B
in the ortho-position relative to the linkage point of the -CONR4- group;

D denotes a phenylene group or a cyclohexylene group in which one or two >CH- units may be replaced by N- atoms;

E denotes a bond, a methyleneoxy group bound to group D
through the oxygen atom, or a straight-chain C1-5-alkylene group which may be substituted by an R5NH-group;

R5 denotes a hydrogen atom or a (C1-5-alkyl)carbonyl, C1-4alkyl-sulphonyl, or benzylsulphonyl group;

and the tautomers, stereoisomers and salts thereof.

4. Compounds of formula I according to claim 1, wherein Ra denotes a hydrogen atom or a C1-4-alkyl or cyclohexyl group;

A denotes a piperidinyl or 3,4-dehydro-piperidinyl group linked to group B via the 4-position, wherein the nitrogen atom is optionally substituted by a group Rb or A denotes a 4-piperazinyl group optionally substituted by a group Rb in the 1-position, or A denotes a quinuclidinyl group;

Rb denotes a (C1-4-alkoxy)carbonyl group;

B denotes a phenylene group;

C denotes a -CONR4 group;

R4 denotes a hydrogen atom or a methyl group or, if C
denotes a -CONR4 group bound to group B via the carbonyl group, R4 may also represent a methylene or 1,2-ethylene group bound to the carbon atom of group B in the ortho-position relative to the point of linkage of the -CONR4 group;

D denotes a 1,4-phenylene or 1,4-cyclohexylene group;

E denotes a bond or a 1,2-ethylene group optionally substituted by an R5NH- group; and Rs denotes a (C1-5-alkyl)carbonyl or a C1-4-alkylsulphonyl group;

and the tautomers, stereoisomers and salts thereof.
5. Compounds of formula I according to claim 1 being 4-[4-[Ctrans-4-[2-(methoxycarbonyl)-ethyl]-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine, 4-[4-[[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine, 4-[4-[[trans-4-(2-carboxyethyl)-cyclohexyl]-aminocarbonyl]-phenyl]-piperidine, 4-[4-[[4-[2-(n-butanesulphonylamino)-2-carboxyethyl]-phenyl]-aminocarbonyl] phenyl]-piperidine, 4-[3-[[4-[2-(n-butanesulphonylamino)-2-carboxyethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine and 4-[3-[[4-[2-(n-butanesulphonylamino)-2-(methoxycarbonyl)-ethyl]-phenyl]-aminocarbonyl]-phenyl]-piperidine, and the tautomers, stereoisomers and salts thereof.
6. A compound as claimed in any one of claims l to 5 in the form of a physiologically acceptable addition salt with an inorganic or organic acid or base.
7. A pharmaceutical composition comprising a compound of formula I as claimed in any one of claims l to 5 or a physiologically acceptable addition salt thereof together with at least one physiologically acceptable carrier or excipient.
8. A process for preparing a compound as claimed in any one of claims l to 5, said process comprising at least one of the following steps:

a) (to prepare compounds of formula I wherein Ra denotes a hydrogen atom) hydrolysing, pyrrolysing or hydrogenolysing a compound of formula II

A - B - C - D - E - COORa' (II) (wherein A, B, C, D and E are defined as in any one of claims 1 to 5 and Ra' has the meanings given for Ra in any one of claims 1 to 5, with the exception of the hydrogen atom);

b) (to prepare compounds of formula I wherein A is substituted by a group Rb) reacting a compound of formula III

A1 - B - C - D - E - COORa (III) (wherein B, C, D, E and Ra are as defined in any one of claims 1 to 5 and A1 denotes a C1-5-aminoalkyl group linked to group B via a carbon atom or a 5-, 6- or 7-membered azacycloalkyl group linked to group B via a carbon atom, wherein the carbon atoms of the azacycloalkyl group may be substituted by one, two, or three C1-3-alkyl groups, or by an aminocarbonyl, cyano, R3O- or R3O-CO- group (wherein R3 is defined as in any one of claims 1 to 5)) with a compound of formula IV

R - Z (IV) (wherein Rb is defined as in any one of claims 1 to 5 and Z1 denotes a nucleophilic leaving group or, if Z1 is bound to a carbonyl group, it may also denote a hydroxy, alkanoyloxy or alkoxycarbonyloxy group, or in the presence of a reducing agent when Z1 together with an adjacent hydrogen atom of the group Rb denotes an oxygen atom);
c) (to prepare compounds of formula I wherein Ra is defined as in any one of claims l to S with the exception of the hydrogen atom) reacting a compound of formula V
A - B - C - D - E - COOH (V) (wherein A, B, C, D and E are defined as in any one of claims 1 to 5) with a compound of formula VI

Z2 - Ra' (VI) (wherein Ra' has the meanings given for Ra in any one of claims 1 to 5, with the exception of the hydrogen atom, and Z2 denotes a nucleophilic leaving group);

d) (to prepare compounds of formula I wherein C denotes a -CH2-NH- group) reducing a compound of formula VII

A - B - CH=N - D - E - COORa (VII) (wherein A, B, D, E and Ra are defined as in any one of claims 1 to 5);

e) (to prepare compounds of formula I wherein C denotes a -CO-NR4- group) reacting a compound of formula VIII

A2 - B - COOH (VIII) (wherein B is defined as in any one of claims 1 to 5 and A2 denotes a group A substituted at the nitrogen atom by an alkyl, aralkyl, alkanoyl, trifluoroacetyl or alkoxycarbonyl group) with an amine of formula IX

R - NH - D - E - COORa' (IX) (wherein D, E and R4 are defined as in any one of claims 1 to 5 and Ra' has the meanings given for Ra in any one of claims 1 to 5, with the exception of the hydrogen atom);

f) (to prepare compounds of formula I wherein C denotes an -NR4-CO- group) reacting a compound of formula X

A - B - NH-R4 (X) (wherein R4 and B are defined as in any one of claims 1 to 5 and A2 denotes a group A substituted at the nitrogen atom by an alkyl, aralkyl, alkanoyl, trifluoroacetyl or alkoxycarbonyl group) with a carboxylic acid of formula XI

HOOC - D - E - COORa' (XI) (wherein D and E are defined as in any one of claims 1 to 5 and Ra' has the meanings given for Ra in any one of claims 1 to 5 with the exception of the hydrogen atom);

g) (to prepare compounds of formula I wherein A denotes a C1-5-aminoalkyl group linked to group B via a carbon atom) reducing a compound of formula XII

A3 - B - C - D - E - COORa (XII) (wherein B, C, D, E and Ra are defined as in any one of claims 1 to 5 and A3 denotes a cyano or cyanoC1-4alkyl group);

h) (to prepare a compound of formula I wherein R4 denotes a C1-2-alkyl group optionally substituted by a phenyl group) alkylating a compound of formula I wherein R4 denotes a hydrogen atom;

i) performing the process of any one of steps (a) to (h) above on a reagent having a protecting group and subsequently removing the protecting group used;

j) converting a compound of formula I into a salt thereof; and k) resolving a compound of formula I into its isomers.
9. The use of a compound of formula I as claimed in any one of claims l to 5 or a physiologically acceptable salt thereof for the manufacture of a medicament for use in combating inflammation, bone degradation, tumours, metastases, thrombosis and aggregation-related conditions.
10. A method of treatment of the human or non-human animal body to combat inflammation, bone degradation, tumours, metastases, thrombosis and aggregation-related conditions, said method comprising administering to said body a commpound of formula I as defined in any one of claims 1 to 5 or a physiologically acceptable salt thereof.
11. Each and every novel compound, composition, process, method and use herein disclosed.
CA002111035A 1992-12-10 1993-12-08 Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them Abandoned CA2111035A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4241632A DE4241632A1 (en) 1992-12-10 1992-12-10 Carboxylic acid derivatives, medicaments containing these compounds and process for their preparation
DEP4241632.9 1992-12-10

Publications (1)

Publication Number Publication Date
CA2111035A1 true CA2111035A1 (en) 1994-06-11

Family

ID=6474905

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002111035A Abandoned CA2111035A1 (en) 1992-12-10 1993-12-08 Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

Country Status (17)

Country Link
EP (1) EP0604800A1 (en)
JP (1) JPH06239817A (en)
KR (1) KR940014330A (en)
CN (1) CN1094035A (en)
AU (1) AU5230693A (en)
CA (1) CA2111035A1 (en)
CZ (1) CZ270593A3 (en)
DE (1) DE4241632A1 (en)
FI (1) FI935513L (en)
HU (1) HU9303521D0 (en)
IL (1) IL107956A0 (en)
MX (1) MX9307781A (en)
NO (2) NO934501D0 (en)
NZ (1) NZ250391A (en)
PL (1) PL301396A1 (en)
SK (1) SK128193A3 (en)
ZA (1) ZA939230B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811459A (en) * 1994-10-12 1998-09-22 Zeneca Limited Ortho substituted aromatic compounds useful as antagonists of the pain enhancing effects of E-type prostaglandins
US5834468A (en) * 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US5843942A (en) * 1994-07-25 1998-12-01 Zeneca Limited Aromatic amino ethers as pain relieving agents
US5965741A (en) * 1994-08-31 1999-10-12 Zeneca Limited Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief
US5994353A (en) * 1995-06-20 1999-11-30 Zeneca Limited Aromatic compounds and pharmaceutical compositions containing them
US6100258A (en) * 1995-06-20 2000-08-08 Zeneca Limited Aromatic amine compounds that antagonize the pain enhancing effects of prostaglandins
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
US7649110B2 (en) 2004-02-27 2010-01-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
US9145354B2 (en) 2011-11-01 2015-09-29 Astex Therapeutics Limited Pharmaceutical compounds

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4326344A1 (en) * 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamides, pharmaceutical compositions containing these compounds and process for their preparation
RU2156763C2 (en) * 1994-07-15 2000-09-27 Мейдзи Сейка Кабусики Кайся Nitrogen-containing heterocyclic derivatives, pharmaceutical composition based on said and method of treatment or prophylaxis of thrombotic diseases
US6069143A (en) * 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
DE19614204A1 (en) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carboxylic acid derivatives, medicaments containing these compounds, their use and processes for their preparation
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
AU6320998A (en) * 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
PT1379520E (en) 2001-02-23 2006-08-31 Merck & Co Inc NMDA / NR2B NON-SUBSTITUTED ANTAGONISTS (NAO-ARIL) -HETEROCYCLICS
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DE602004017703D1 (en) * 2003-02-24 2008-12-24 Arena Pharm Inc PHENYL AND PYRIDYL PIPERIDINE DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
JP4875978B2 (en) * 2004-03-15 2012-02-15 武田薬品工業株式会社 Aminophenylpropanoic acid derivatives
DOP2006000010A (en) 2005-01-10 2006-07-31 Arena Pharm Inc PROCEDURE TO PREPARE AROMATIC ETERES
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
CN116850181A (en) 2015-01-06 2023-10-10 艾尼纳制药公司 Treatment and S1P 1 Methods of receptor-related disorders
AU2016284162A1 (en) 2015-06-22 2018-02-01 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2019236757A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402975A (en) * 1980-07-21 1983-09-06 Teijin Limited Aminocarboxylic acids, amino alcohols, or the derivatives thereof, processes for production thereof, and pharmaceutical uses thereof
DE3718638A1 (en) * 1987-06-04 1988-12-22 Thomae Gmbh Dr K NEW PHENYLETHANOLAMINE, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
IL99538A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
DE4035961A1 (en) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
DE4102024A1 (en) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K BIPHENYL DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND METHOD FOR THE PRODUCTION THEREOF
DE4127404A1 (en) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
DE4213919A1 (en) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
DE4213931A1 (en) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843942A (en) * 1994-07-25 1998-12-01 Zeneca Limited Aromatic amino ethers as pain relieving agents
US5965741A (en) * 1994-08-31 1999-10-12 Zeneca Limited Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief
US5811459A (en) * 1994-10-12 1998-09-22 Zeneca Limited Ortho substituted aromatic compounds useful as antagonists of the pain enhancing effects of E-type prostaglandins
US5994353A (en) * 1995-06-20 1999-11-30 Zeneca Limited Aromatic compounds and pharmaceutical compositions containing them
US6100258A (en) * 1995-06-20 2000-08-08 Zeneca Limited Aromatic amine compounds that antagonize the pain enhancing effects of prostaglandins
US6313148B1 (en) 1995-06-20 2001-11-06 Zeneca Limited Aromatic amine compounds that antagnoize the pain enhancing effects of prostaglandins
US5834468A (en) * 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US6787562B2 (en) 1995-07-07 2004-09-07 Zeneca Ltd. Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US7649110B2 (en) 2004-02-27 2010-01-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
US8003648B2 (en) 2006-09-07 2011-08-23 Amgen Inc. Heterocyclic GPR40 modulators
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
US9145354B2 (en) 2011-11-01 2015-09-29 Astex Therapeutics Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
JPH06239817A (en) 1994-08-30
NO934501L (en) 1994-06-13
HU9303521D0 (en) 1994-04-28
FI935513A0 (en) 1993-12-09
CZ270593A3 (en) 1994-11-16
KR940014330A (en) 1994-07-18
ZA939230B (en) 1995-06-09
MX9307781A (en) 1994-06-30
EP0604800A1 (en) 1994-07-06
AU5230693A (en) 1994-06-23
CN1094035A (en) 1994-10-26
FI935513A7 (en) 1994-06-11
NZ250391A (en) 1996-06-25
NO934501D0 (en) 1993-12-09
IL107956A0 (en) 1994-04-12
DE4241632A1 (en) 1994-06-16
FI935513L (en) 1994-06-11
PL301396A1 (en) 1994-07-25
SK128193A3 (en) 1995-02-08

Similar Documents

Publication Publication Date Title
CA2111035A1 (en) Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US5700801A (en) Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US5688960A (en) Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
CA2108093A1 (en) Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US5534525A (en) Lactam derivatives
CA2129374A1 (en) Carbonamides, pharmaceutical compositions containing these compounds and processes for their preparation
WO2004037810A1 (en) Selected cgrp antagonists, method for production and use thereof as medicament
CA2098158A1 (en) Biphenyl derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
JPH0625159A (en) Cyclic imino derivatives, medicinal compositions containing them and their preparation
JPH0770137A (en) Bicyclic heterocyclic compounds, pharmaceutical formulations containing these compounds and methods for their preparation
IE893050L (en) 1-£(diarylmethoxy)alkyl|pyrrolidines and piperidines
US5641772A (en) Condensed diazepinones, processes for preparing them and agents containing these compounds for treating diseases of the central nervous system and for promoting cerebral blood circulation
NO170580B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PIPERIDE INGREDIENTS
AU703946B2 (en) Substituted phenylamidines, pharmaceutical compositions containing these compounds and processes for preparing them
US11008317B2 (en) Triazolopyridine inhibitors of myeloperoxidase and/or EPX
US5945428A (en) Substituted oximes, hydrazones and olefins as neurokinin antagonists
AU619049B2 (en) New 1,4-dihydropyridinederivative, namely (-)-2-{(2- aminoethoxy) ethoxy)-4-(2,3-dichlorophenyl)-3- ethoxycarbonyl-50methoxycarbonyl-6-methyl}-1,4- dihydropyridine, process for preparing it and pharmaceutical compositions containing it
SK1052001A3 (en) Substituted phenylamidines with antithrombotic action
DE4424975A1 (en) 2-Piperidinones, medicaments containing these compounds and process for their preparation
EP0937076B1 (en) Substituted oximes, hydrazones and olefins as neurokinin antagonists
DE19607436A1 (en) New carboxylic acid compounds useful e.g. as antiinflammatory or antithrombotic agents
US6242466B1 (en) Substituted phenylamidines
US5244907A (en) Carbocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents
MXPA00012835A (en) Substituted phenylamidines with antithrombotic action

Legal Events

Date Code Title Description
FZDE Discontinued